[Minor salmonellosis in pediatrics: cases at the Pediatric Clinic I].

M. di Tullio,F. Casale,K. Marchi,P. Indolfi,N. Cinque,A. Morelli

1980-09-30

Abstract:

What problem does this paper attempt to address?

Definition of the Post-COVID syndrome using a symptom-based Post-COVID score in a prospective, multi-center, cross-sectoral cohort of the German National Pandemic Cohort Network (NAPKON)

Katharina S. Appel,Carolin Nürnberger,Thomas Bahmer,Christian Förster,Maria Cristina Polidori,Mirjam Kohls,Tanja Kraus,Nora Hettich-Damm,Julia Petersen,Sabine Blaschke,Isabel Bröhl,Jana Butzmann,Hiwa Dashti,Jürgen Deckert,Michael Dreher,Karin Fiedler,Carsten Finke,Ramsia Geisler,Frank Hanses,Sina M. Hopff,Björn-Erik O. Jensen,Margarethe Konik,Kristin Lehnert,Susana M. Nunes de Miranda,Lazar Mitrov,Olga Miljukov,Jens-Peter Reese,Gernot Rohde,Margarete Scherer,Kristin Tausche,Johannes J. Tebbe,Jörg Janne Vehreschild,Florian Voit,Patricia Wagner,Martin Weigl,Christina Lemhöfer,K. Alsaad,E. Hamelmann,H Heidenreich,C. Hornberg,N. S. A. Kulamadayil-Heidenreich,P. Maasjosthusmann,A. Muna,M. Ruwe,C. Stellbrink,N. Buechner,Y. Dashti,C. Tessmer,B. Laumerich,I. Silberbaur,S. Bader,M. Engelmann,A. Fuchs,A. Langer,B. Maerkl,H. Messmann,A. Muzalyova,C. Roemmele,H. Altmann,R. Berner,S. Dressen,T. Koch,D. Lindemann,K. Seele,P. Spieth,N. Toepfner,S. V. Bonin,T. Feldt,V. Keitel,A. Killer,L. Knopp,T. Luedde,M. Lutterbeck,M. Paluschinski,J. P. V. Pereira,J. Timm,D. Kraska,A. E. Kremer,M. Leppkes,J. Mang,M. F. Neurath,H. U. Prokosch,J. Schmid,M. Vetter,C. Willam,K. Wolf,C. Arendt,C. Bellinghausen,S. Cremer,A. Groh,A. Gruenewaldt,Y. Khodamoradi,S. Klinsing,M. Vehreschild,T. Vogl,M. Addo,M. Almahfoud,A. L. F. Engels,D. Jarczak,M. Kerinn,S. Kluge,R. Kobbe,S. Petereit,C. Schlesner,T. Zeller,R. Baber,S. Bercker,N. Krug,S. D. Mueller,H. Wirtz,G. Boeckel,J. A. Meier,T. Nowacki,P. R. Tepasse,R. Vollenberg,C. Wilms,E. Dahl,N. Marx,D. Mueller-Wieland,J. Wipperfuerth,C. Brochhausen-Delius,R. Burkhardt,M. Feustel,O. Haag,S. Hansch,M. Malfertheiner,T. Niedermair,P. Schuster,S. Wallner,S. Cleef,A. Friedrichs,N. Kaeding,M. Koerner,C. Kujat,M. Oberlaender,D. Pape,M. Plagge,J. Rupp,D. Schunk,S. Cleef,A. Friedrichs,N. Kaeding,M. Koerner,C. Kujat,M. Oberlaender,D. Pape,M. Plagge,J. Rupp,D. Schunk,W. Barkey,J. Erber,L. Fricke,J. Lieb,T. Michler,L. Mueller,J. Schneider,C. Spinner,C. Winter,M. Bitzer,S. Bunk,S. Göpel,H. Haeberle,K. Kienzle,H Mahrhofer,N. Malek,P. Rosenberger,C. Struemper,F. Trauner,S. Frantz,A. Frey,K. Haas,C. Haertel,J. Herrmann,N. Isberner,J. Liese,P. Meybohm,J. Schmidt,P. Schulze,F. Brinkmann,Y. Brueggemann,T. Gambichler,K. Hellwig,T. Luecke,A. Reinacher-Schick,W. E. Schmidt,C. Schuette,E. Steinmann,C. Torres Reyes,A. Hafke,G. Hermanns,S. Y. Nussbeck,M. Santibanez-Santana,S. Zeh,L. Brochhagen,S. Dolff,C. Elsner,A. Krawczyk,R. J. Madel,M. Otte,O. Witzke,K. Becker,M. Doerr,M Nauck,N. Piasta,C. Schaefer,E. Schaefer,M. Schattschneider,C. Scheer,D. Stahl,A. Arlt,F. Griesinger,U. Guenther,A. Hamprecht,K. Juergens,A. Kluge,C. Meinhardt,K. Meinhardt,A. Petersmann,R. Prenzel,M. Brechtel,M. Laugwitz,C. Lee,G. Sauer,N. Schulze,K. Seibel,M. Stecher,M. Hagen,J. Schneider,S. Sikdar,C. Weismantel,L. Wolf,K. Günther,J. Haug,F. Haug,C. Fiessler,P. U. Heuschmann,L. Schmidbauer,S. Jiru-Hillmann,T. Bahls,W. Hoffmann,M. Nauck,C. Schaefer,M. Schattschneider,D. Stahl,H. Valentin,I. Chaplinskaya,S. Hanß,D. Krefting,C. Pape,M. Rainers,A. Schoneberg,N. Weinert,M. Kraus,B. Lorenz-Depiereux,R. Lorbeer,J. Schaller,J. Fricke,L. Krist,M. Rönnefarth,S. Schmidt,T. Bahmer,A. Hermes,M. Krawczak,W. Lieb,S. Schreiber,T. Tamminga,S. Herold,P. Heuschmann,R. Heyder,W. Hoffmann,T. Illig,S. Schreiber,M. Witzenrath,the NAPKON Study Group

DOI: https://doi.org/10.1007/s15010-024-02226-9

2024-04-09

Infection

Abstract:Purpose The objective examination of the Post-COVID syndrome (PCS) remains difficult due to heterogeneous definitions and clinical phenotypes. The aim of the study was to verify the functionality and correlates of a recently developed PCS score. Methods The PCS score was applied to the prospective, multi-center cross-sectoral cohort (in- and outpatients with SARS-CoV-2 infection) of the "National Pandemic Cohort Network (NAPKON, Germany)". Symptom assessment and patient-reported outcome measure questionnaires were analyzed at 3 and 12 months (3/12MFU) after diagnosis. Scores indicative of PCS severity were compared and correlated to demographic and clinical characteristics as well as quality of life (QoL, EQ-5D-5L). Results Six hundred three patients (mean 54.0 years, 60.6% male, 82.0% hospitalized) were included. Among those, 35.7% (215) had no and 64.3% (388) had mild, moderate, or severe PCS. PCS severity groups differed considering sex and pre-existing respiratory diseases. 3MFU PCS worsened with clinical severity of acute infection ( p = .011), and number of comorbidities ( p = .004). PCS severity was associated with poor QoL at the 3MFU and 12MFU ( p < .001). Conclusion The PCS score correlated with patients' QoL and demonstrated to be instructive for clinical characterization and stratification across health care settings. Further studies should critically address the high prevalence, clinical relevance, and the role of comorbidities. Trail registration number The cohort is registered at www.clinicaltrials.gov under NCT04768998.

infectious diseases
Epidemiology of 7375 children and adolescents hospitalized with COVID-19 in Germany, reported via a prospective, nationwide surveillance study in 2020–2022

Maren Doenhardt,Markus Hufnagel,Natalie Diffloth,Johannes Hübner,René Mauer,Dominik T. Schneider,Arne Simon,Tobias Tenenbaum,Andreas Trotter,Jakob Armann,Reinhard Berner,Aischa Abuleed,Michal Achenbach,Grazyna Adamiak-Brych,Martina Aderhold,Sandra Akanbi,Madaa Akmeinasi,Norbert Albers,Louisa Ammann-Schnell,Kristin Anders,Theresa Andree,Judith Anhalt,Nils Apel,Stefan Arens,Christoph Aring,Caroline Armbruster,Inken Arnold,Thomas Austgen,Igor Bachmat,Lena Balles,Arne Baltaci,Theresa Baranowski,Sylvia Barth,Stefan Barth,María Paula Bateman Castrillón,Susanne Baumann,Lisa Baumbach,Boris Becker,Angelina Beer,Gerald Beier,Christiane Bell,Antigoni Bellou,Stephanie Bentz,Josephine Berens,Elisabeth Berger,Simon Berzel,Julia Bley,Helga Blumberg,Stefanie Blume,Kai Böckenholt,Andreas Böckmann,Sebastian Bode,Julie Boever,Leonie Böhm,Henning Böhme,Carsten Bölke,Monika-Maria Borchers,Hans Martin Bosse,Michael Böswald,Katharina Botschen,Franka Böttger,Sandra Braun,Britta Brenner,Folke Brinkmann,Beate Bruggmoser,Jürgen Brunner,Florian L. Bucher,Laura Buchtala,Jörg Budde,Reinhard Bullmann,Bernhard Bungert,Dorothea Büsdorf,Lisa Cardellini,Chiara Cattaneo,Cho-Ming Chao,Laura Chaparro,Claus Christians,Kerstin Cremer,Gordana Cvetanovic,Alina Czwienzek,Madura Daluwatta,Gideon de Sousa,Metin Degirmenci,Fenja Dejas,Janne Deutschmann,Ute Deutz,Iryna Dobrianska,Katharina Döhring,Helena Donath,Arne Dresen,Svenja Dreßen,Melissa Drozdek,Jens Dubenhorst,Max Dunker,Heinrich Eberhardt,Franziska Ebert,Hannah Echelmeyer,Kerstin Ehrentraut,Christoph Ehrsam,Thea Angelika Eichelmann,Hanna Ellmann,Matthias Endmann,Stefanie Endres,Elisa Endres,Matthias Engler,Denise Engler,David Eppler,Oxana Erbe,Michael Erdmann,Annika Esser,Stephan Ewest,Philipp Falderbaum,Lena Faßbender,Simone Ferber,Andreas Fiedler,Magdalena Fischer,Doris Fischer,Elisabeth Fischer-Ging,Isabel Fischer-Schmidt,Ann-Sophie Fleischer,Simon Flümann,Denise Focke,Svenja Foth,Réka Fövényesi,Svenja Frank,Christian Fremerey,Holger Frenzke,Peter Freudenberg,Mirjam Freudenhammer,Christina Fritsch,Stefanie Frohn,Sylvia Fuhrmann,Veronika Galajda Pavlíková,Lukas Galow,Monika Gappa,Sabine Gärtner,Hanga Gaspar,Swen Geerken,Julia Gehm,Fabienne Gehrlein,Norbert Geier,Bernd Geißlreiter,Martin Geltinger,Marieke Gerlach,Hubert Gerleve,Carl Germann,Verena Giesen,Anna Girrbach,Katharina Glas,Lena Goetz,Karoline Goj,Christin Goldhardt,Julia Gottschalk,Jan-Felix Gottschlich,Oliver Götz,Katrin Gröger,Sina Gronwald,Anja Große Lordemann,Anneke Grotheer,Kathrin Gruber,Judith Grüner,Mike Grünwedel,Lisa Gu,Joya Gummersbach,Stephan Haag,Silke Haag,Yasmin Hagel,Swantje Hagemann,Ina Hainmann,Nikolaus Halwas,Christof Hanke,Jonas Härtner,Caroline Haselier,Anne Haupt,Marie- Kristin Heffels,Solvej Heidtmann,Anna-Lena Heimer,Christina Heinrich,Annika Heinrich,Lutz Hempel,Christoph Hempel,Silke Hennig,Carolin Herbst,Leonie Herholz,Matthias Hermann,Jan-Simon Hermens,Marc Hertel,Matthias Herzog,Georg Heubner,Julia Hildebrandt,Kai-Alexandra Hilker,Georg Hillebrand,Matthias Himpel,Claudia Hirschhausen,Meike Höfer,Liane Hoffmann,Hans-Georg Hoffmann,Mirjam Höfgen,Nina Hofknecht,Anja Hofmann,Franziska Hofmann,Katharina Holtkamp,Mona Holzinger,Anneke Homburg,Thomas Hoppen,Theresa Horst,Andor Attila Horváth,Markus Hummler,Patrick Hundsdörfer,Dieter Hüseman,Conny Huster,Nora Ido,Phryne Ioannou,Simone Jedwilayties,Nils Jonas,Cornelia Junge,Linda Junghanns,Attila Kádár,Mohammad Kaddour,Lea Kahlenberg,Lukas Kaiser,Petra Kaiser-Labusch,Hermann Kalhoff,Carola Kaltenhauser,Elke Kaluza,Wolfgang Kamin,Cecil Varna Kanann,Marcus Kania,Cecil Varna Kannan,Subha Kanneettukandathil,Hendrik Karpinski,Fabian Kassbeger,Katja Kauertz,Alexandra Kavvalou,Svetlana Kelzon,Immo Kern,Elisabeth Kernen,Mandy Kersten,Marie-Sophie Keßner,Daniel Kever,Carolin Khakzar,Johanna Kim,Linda Kirner,Martin Kirschstein,Natalie Kiss,Richard Kitz,Christine Kleff,Deborah Klein,Leah Bernadette Klingel,Christof Kluthe,Jan Knechtel,Marcel Kneißle,Felix Knirsch,Robin Kobbe,Annemarie Köbsch,Luisa Kohlen,Christina Kohlhauser-Vollmuth,Malte Kohns Vasconcelos,Anne Königs,Florian Konrad,Sabrina Koop,Julia Kopka,Vanessa Kornherr,Anna-Lena Kortenbusch,Robert Kosteczka,Holger Köster,Sascha Kowski,Hanna Kravets,Ewa Krink,Maren Krogh,Rebecca Kuglin,Reinhard Kühl,Alena Kuhlmann,Lea Maria Küpper-Tetzel,Marion Kuska,Sachiko Kwaschnowitz,Martina Lange,Franziska Lankes,Julia Laubenbacher,Gerrit Lautner,Thanh Tung Le,Verena Leykamm,Hanna Libuschewski,Lissy Lichtenstein,Nadine Lienert,Johannes Liese,Ulla Lieser,Ilona Lindl,Torben Lindner,Grischa Lischetzki,Matthias Lohr,Norbert Lorenz,Niko Lorenzen,Meike Löwe,Daniela Lubitz,Maria Lueg,Lisa Luft,Sa Luo,Dominik Lwowsky,Kathrin Machon,Katharina Magin,Thomas Maiberger,Nadine Mand,Andrea Markowsky,Wiebke Maurer,Maximilian Mauritz,Theresa Meinhold,Jochen Meister,Melanie Menden,Veronika Messer,Jochen Meyburg,Ulf Meyer,Meike Meyer,Jens Meyer,Lars Meyer-Dobkowitz,Peter Michel,Marko Mohorovicic,Laura Gabriela Moise,Katharina Mönch,Mathieu Monnheimer,Yvonne Morawski,Anja Morgenbrod,Katrin Moritz,David Muhmann,Barbara Müksch,Stefanie Müller,Celina Müller,Annemarie Müller,Viola Müller,Yvonne Müller,Guido Müller,Kathleen Müller-Franz,Lutz Naehrlich,Katharina Naghed,Nicole Näther,Tereza Nespor,Tatjana Neuhierl,Ann-Cathrine Neukamm,Nam Nguyen,Dirk Nielsen,Klaus Niethammer,Lydia Obernosterer,Bernd Opgen-Rhein,Iris Östreicher,Esra Özdemir,Nadejda Paduraru-Stoian,Monique Palm,Laura Parigger,Nina Pellmann,Theresa Pelster,Ardina Pengu,Falk Pentek,Maurice Petrasch,Antonia Maximina Pfennigs,Aaron Pfisterer,Anne Pfülb,Lisa Piehler,Ursula Pindur,Markus Pingel,Eva Pitsikoulis,Jana Plutowski,Wendy Poot,Silvia Poralla,Johanna Pottiez,Simone Pötzsch,Pablo Pretzel,Clarissa Preuß,Sven Propson,Kateryna Puhachova,Daniela Pütz,Samina Quadri-Niazi,Bernhard Queisser,Jennifer Rambow,Gunnar Rau,Cornelius Rau,Jacqueline Raum,Heike Reck,Victoria Rehmann,Friedrich Reichert,Thomas Reinhardt,Carla Remy,Hanna Renk,Annika Richard,Carolin Richter,Nikolaus Rieber,Sebastian Riedhammer,Hannelore Ringe,Bianca Rippberger,Moritz Rohrbach,Bettina Rokonal,Caroline Rötger,Anne Rothermel,Ricarda Rox,Alexander Rühlmann,Marie-Cecile Ryckmanns,Shahane Safarova,Meila Salem,Demet Sarial,Helena Sartor,Johanna Saxe,Herbert Schade,Miriam Schäfer,Cecilia Scheffler,Lena Brigitte Scheffler,Marija Scheiermann,Sandra Schiele,Katja Schierloh,Markus Schiller,Benjamin Schiller,Ruth Schilling,Christof Schitke,Christian Schlabach,Theresa Schlichting,Christian Schlick,Christina Schlingschröder,Florian Schmid,Bastian Schmidt,Josephine Schneider,Dominik Schneider,Hans-Christoph Schneider,Alexander Schnelke,Axel Schobeß,Lothar Schrod,Arne Schröder,Sophia Schröder,Theresia Schug,Christopher Schulze,Katharina Schuster,Katharina Schütz,Valeria Schwägerl,Christoffer Seidel,Christina Seidel,Sabrina Seidel,Josephin Seidel,Katrin Seringhaus-Förster,Armin Setzer,Ralf Seul,Wael Shabanah,M. Ghiath Shamdeen,Sebastian Sigl,Isabel Simon,Christina Solomou,Ezgi Sönmez,Lisa Spath,Marco Spehl,Thomas Stanjek,Daniel Staude,Janina Steenblock,Sandro Stehle,Michael Steidl,Benedikt Steif,Detlef Stein,Franziska Stein,Mathis Steindor,Frank Stemberg,Susanne Stephan,Astrid Stienen,Antje Stockmann,Ursula Strier,Heidi Ströle,Roman Szudarek,Van Hop Ta,Kader Tan,Rebecca Telaar,Anna Telschow,Lisa Teufel,Stephanie Thein,Lion Gabriel Thiel,Lisa Thiesing,Linda Thomas,Julian Thomas,Christian Timke,Irmgard Toni,Melcan Topuz,Stefanie Trau,Eva Tschiedel,Sinty Tzimou,Felix Uhlemann,Torsten Uhlig,Lieser Ulla,Bartholomäus Urgatz,Nicolaus v. Salis,Sascha v. Soldenhoff,Louisa van Bahlen,Alijda Ingeborg van den Heuvel,Kai Vehse,Rebecca Veit,Joshua Verleysdonk,Andreas Viechtbauer,Simon Vieth,Markus Vogel,Sophia von Blomberg,Kira von der Decken,Christian von Schnakenburg,Julia Wagner,Tatjana Wahjudi,Karin Waldecker,Ulrike Walden,Ulrike Walther,Mona Walther,Christine Wegendt,Götz Wehl,Stefan Weichert,Judith Anne Weiland,Julia Weiß,Laura Wendt,Vera Wentzel,Cornelia Wersal,Ulrike Wetzel,Barbara Wichmann,Katharina Wickert,Sandra Wieland,Christiane Maria Wiethoff,Hanna Wietz,Florian Wild,Rainer Willing,Christian Windischmann,Verena Winkeler,Merle Winkelmann,Sascha Winkler,Laura Wißlicen,Isabel Wormit-Frenzel,Tobias Wowra,Andreas Wroblewski,Dominik Wulf,Donald Wurm,Malin Zaddach,Julia Zahn,Kai Zbieranek,Lara-Sophie Zehnder,Anne Zeller,Martin Zellerhoff,Katharina Zerlik,Johanna Zimmermann,Mária Zimolová,Ulrich Zügge,The DGPI COVID-19 working group

DOI: https://doi.org/10.1038/s41598-023-49210-1

IF: 4.6

2024-01-03

Scientific Reports

Abstract:By means of a nationwide, prospective, multicenter, observational cohort registry collecting data on 7375 patients with laboratory-confirmed SARS-CoV-2 admitted to children's hospitals in Germany, March 2020–November 2022, our study assessed the clinical features of children and adolescents hospitalized due to SARS-CoV-2, evaluated which of these patients might be at highest risk for severe COVID-19, and identified underlying risk factors. Outcomes tracked included: symptomatic infection, case fatality, sequelae at discharge and severe disease. Among reported cases, median age was one year, with 42% being infants. Half were admitted for reasons other than SARS-CoV-2. In 27%, preexisting comorbidities were present, most frequently obesity, neurological/neuromuscular disorders, premature birth, and respiratory, cardiovascular or gastrointestinal diseases. 3.0% of cases were admitted to ICU, but ICU admission rates varied as different SARS-CoV-2 variants gained prevalence. Main risk factors linked to ICU admission due to COVID-19 were: patient age (> 12 and 1–4 years old), obesity, neurological/neuromuscular diseases, Trisomy 21 or other genetic syndromes, and coinfections at time of hospitalization. With Omicron, the group at highest risk shifted to 1–4-year-olds. For both health care providers and the general public, understanding risk factors for severe disease is critical to informing decisions about risk-reduction measures, including vaccination and masking guidelines.

multidisciplinary sciences
From first to second wave: follow-up of the prospective COVID-19 cohort (KoCo19) in Munich (Germany)

Katja Radon,Abhishek Bakuli,Peter Pütz,Ronan Le Gleut,Jessica Michelle Guggenbuehl Noller,Laura Olbrich,Elmar Saathoff,Mercè Garí,Yannik Schälte,Turid Frahnow,Roman Wölfel,Michael Pritsch,Camilla Rothe,Michel Pletschette,Raquel Rubio-Acero,Jessica Beyerl,Dafni Metaxa,Felix Forster,Verena Thiel,Noemi Castelletti,Friedrich Rieß,Maximilian N. Diefenbach,Günter Fröschl,Jan Bruger,Simon Winter,Jonathan Frese,Kerstin Puchinger,Isabel Brand,Inge Kroidl,Andreas Wieser,Michael Hoelscher,Jan Hasenauer,Christiane Fuchs,Nikolaus Ackermann,Emad Alamoudi,Jared Anderson,Maxilmilian Baumann,Marc Becker,Franziska Bednarzki,Olimbek Bemirayev,Patrick Bitzer,Rebecca Böhnlein,Friedrich Caroli,Josephine Coleman,Lorenzo Contento,Alina Czwienzek,Flora Deák,Jana Diekmannshemke,Gerhard Dobler,Jürgen Durner,Ute Eberle,Judith Eckstein,Tabea Eser,Philine Falk,Manuela Feyereisen,Volker Fingerle,Otto Geisenberger,Christof Geldmacher,Leonard Gilberg,Kristina Gillig,Philipp Girl,Elias Golschan,Elena Maria Guglielmini,Pablo Gutierrez,Anslem Haderer,Marlene Hannes,Lena Hartinger,Alejandra Hernandez,Leah Hillari,Christian Hinske,Tim Hofberger,Sacha Horn,Kristina Huber,Christian Janke,Ursula Kappl,Antonia Keßler,Zohaib Khan,Johanna Kresin,Arne Kroidl,Magdalena Lang,Clemens Lang,Silvan Lange,Michael Laxy,Reiner Leidl,Leopold Liedl,Xhovana Lucaj,Fabian Luppa,Alexandra Sophie Nafziger,Petra Mang,Alisa Markgraf,Rebecca Mayrhofer,Hannah Müller,Katharina Müller,Ivana Paunovic,Michael Plank,Claire Pleimelding,Stephan Prückner,Elba Raimúndez,Jakob Reich,Viktoria Ruci,Nicole Schäfer,Benedikt Schluse,Lara Schneider,Mirjam Schunk,Lars Schwettmann,Andreas Sing,Alba Soler,Peter Sothmann,Kathrin Strobl,Jeni Tang,Fabian Theis,Sophie Thiesbrummel,Vincent Vollmayr,Emilia von Lovenberg,Jonathan von Lovenberg,Julia Waibel,Claudia Wallrauch,Julia Wolff,Tobias Würfel,Houda Yaqine,Sabine Zange,Eleftheria Zeggini,Anna Zielke,Thorbjörn Zimmer,

DOI: https://doi.org/10.1186/s12879-021-06589-4

IF: 3.7

2021-09-08

BMC Infectious Diseases

Abstract:Abstract Background In the 2nd year of the COVID-19 pandemic, knowledge about the dynamics of the infection in the general population is still limited. Such information is essential for health planners, as many of those infected show no or only mild symptoms and thus, escape the surveillance system. We therefore aimed to describe the course of the pandemic in the Munich general population living in private households from April 2020 to January 2021. Methods The KoCo19 baseline study took place from April to June 2020 including 5313 participants (age 14 years and above). From November 2020 to January 2021, we could again measure SARS-CoV-2 antibody status in 4433 of the baseline participants (response 83%). Participants were offered a self-sampling kit to take a capillary blood sample (dry blood spot; DBS). Blood was analysed using the Elecsys ® Anti-SARS-CoV-2 assay (Roche). Questionnaire information on socio-demographics and potential risk factors assessed at baseline was available for all participants. In addition, follow-up information on health-risk taking behaviour and number of personal contacts outside the household (N = 2768) as well as leisure time activities (N = 1263) were collected in summer 2020. Results Weighted and adjusted (for specificity and sensitivity) SARS-CoV-2 sero-prevalence at follow-up was 3.6% (95% CI 2.9–4.3%) as compared to 1.8% (95% CI 1.3–3.4%) at baseline. 91% of those tested positive at baseline were also antibody-positive at follow-up. While sero-prevalence increased from early November 2020 to January 2021, no indication of geospatial clustering across the city of Munich was found, although cases clustered within households. Taking baseline result and time to follow-up into account, men and participants in the age group 20–34 years were at the highest risk of sero-positivity. In the sensitivity analyses, differences in health-risk taking behaviour, number of personal contacts and leisure time activities partly explained these differences. Conclusion The number of citizens in Munich with SARS-CoV-2 antibodies was still below 5% during the 2nd wave of the pandemic. Antibodies remained present in the majority of SARS-CoV-2 sero-positive baseline participants. Besides age and sex, potentially confounded by differences in behaviour, no major risk factors could be identified. Non-pharmaceutical public health measures are thus still important.

infectious diseases
Analysis of acute COVID-19 including chronic morbidity: protocol for the deep phenotyping National Pandemic Cohort Network in Germany (NAPKON-HAP)

Fridolin Steinbeis,Charlotte Thibeault,Sarah Steinbrecher,Yvonne Ahlgrimm,Ira An Haack,Dietrich August,Beate Balzuweit,Carla Bellinghausen,Sarah Berger,Irina Chaplinskaya-Sobol,Oliver Cornely,Patrick Doeblin,Matthias Endres,Claudia Fink,Carsten Finke,Sandra Frank,Sabine Hanß,Tim Hartung,Johannes Christian Hellmuth,Susanne Herold,Peter Heuschmann,Jan Heyckendorf,Ralf Heyder,Stefan Hippenstiel,Wolfgang Hoffmann,Sebastian Ulrich Kelle,Philipp Knape,Philipp Koehler,Lucie Kretzler,David Manuel Leistner,Jasmin Lienau,Roberto Lorbeer,Bettina Lorenz-Depiereux,Constanze Dorothea Lüttke,Knut Mai,Uta Merle,Lil Antonia Meyer-Arndt,Olga Miljukov,Maximilian Muenchhoff,Moritz Müller-Plathe,Julia Neuhann,Hannelore Neuhauser,Alexandra Nieters,Christian Otte,Daniel Pape,Rafaela Maria Pinto,Christina Pley,Annett Pudszuhn,Philipp Reuken,Siegberg Rieg,Petra Ritter,Gernot Rohde,Maria Rönnefarth,Michael Ruzicka,Jens Schaller,Anne Schmidt,Sein Schmidt,Verena Schwachmeyer,Georg Schwanitz,Werner Seeger,Dana Stahl,Nicole Stobäus,Hans Christian Stubbe,Norbert Suttorp,Bettina Temmesfeld,Sylvia Thun,Paul Triller,Frederik Trinkmann,Istvan Vadasz,Heike Valentin,Maria Vehreschild,Christof von Kalle,Marie von Lilienfeld-Toal,Joachim Weber,Tobias Welte,Christian Wildberg,Robert Wizimirski,Saskia Zvork,Leif Erik Sander,Janne Vehreschild,Thomas Zoller,Florian Kurth,Martin Witzenrath

DOI: https://doi.org/10.1007/s15010-023-02057-0

Infection

Abstract:Background: The severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) pandemic causes a high burden of acute and long-term morbidity and mortality worldwide despite global efforts in containment, prophylaxis, and therapy. With unprecedented speed, the global scientific community has generated pivotal insights into the pathogen and the host response evoked by the infection. However, deeper characterization of the pathophysiology and pathology remains a high priority to reduce morbidity and mortality of coronavirus disease 2019 (COVID-19). Methods: NAPKON-HAP is a multi-centered prospective observational study with a long-term follow-up phase of up to 36 months post-SARS-CoV-2 infection. It constitutes a central platform for harmonized data and biospecimen for interdisciplinary characterization of acute SARS-CoV-2 infection and long-term outcomes of diverging disease severities of hospitalized patients. Results: Primary outcome measures include clinical scores and quality of life assessment captured during hospitalization and at outpatient follow-up visits to assess acute and chronic morbidity. Secondary measures include results of biomolecular and immunological investigations and assessment of organ-specific involvement during and post-COVID-19 infection. NAPKON-HAP constitutes a national platform to provide accessibility and usability of the comprehensive data and biospecimen collection to global research. Conclusion: NAPKON-HAP establishes a platform with standardized high-resolution data and biospecimen collection of hospitalized COVID-19 patients of different disease severities in Germany. With this study, we will add significant scientific insights and provide high-quality data to aid researchers to investigate COVID-19 pathophysiology, pathology, and chronic morbidity.
Intensive heart rhythm monitoring to decrease ischemic stroke and systemic embolism-the Find-AF 2 study-rationale and design

Tobias Uhe,Katrin Wasser,Mark Weber-Krüger,Wolf-Rüdiger Schäbitz,Martin Köhrmann,Johannes Brachmann,Ulrich Laufs,Martin Dichgans,Götz Gelbrich,David Petroff,Christiane Prettin,Dominik Michalski,Andrea Kraft,Thorleif Etgen,Peter D Schellinger,Hassan Soda,Florian Bethke,Michael Ertl,Bernd Kallmünzer,Martin Grond,Katharina Althaus,Gerhard F Hamann,Meinhard Mende,Marcus Wagner,Sonja Gröschel,Timo Uphaus,Klaus Gröschel,Rolf Wachter,Find-AF 2 study group,Marianne Hahn,Frederic Zuhorn,Leonard Wulff,Jorge Plümer,Lena Kok,Marcel Janz,Alkisti Kitsiou,Julian Gehmeyr,Alhuda Dabbagh,Charlotte Huber,Johann Pelz,Katja Wartenberg,Mirko Seidel,Oscar Flissakowski,Anna Goschenhofer,Rabia-Basari Hussain,Ina Kim,Stephan Kinze,Christian Kroneberger,Michale Lingnau,Dennis Lischewski,Florian Muhn,Witold Rogge,Miriam Schieffer,Anuscheh Setayesh-Roonizi,Paul Sparenberg,Jill Marie Schertel,Peter Ringleb,Jan Purrucker,Anne Berberich,Miriam Heyse,Matthias Ungerer,Gregor Bauer,Christine Reichardt,Bernhard Ebel,Dragana Milanković-Eberl,Olav Schwarte,Constanze Höcherl,Eric-Manuel Asch,Luisa Bojtschuk,Maximilian Frey,Tomas Dlouhy,Philipp Patrick Zickler,Barbara Beier,Lino-Dominic Braadt,Inessa Gabrielyan,Pawel Kermer,Matthias Kaste,Ahmed Anter,Corina Stirbulescu,Nataliia Meleshchenco,Friederike Burgholte,Claus Lüers,Thorsten Steiner,Cierpinski,Lichti Mari-Carmen,Lars Bonowski,Hassan Abou Eid,Esteban Vajda-Medina,Mareike Probst,Hisham Essa,Benedikt Frank,Benjamin Stolte,Lennart Milles,Erich Hiermann,Renate Weinhardt Alexandra Rascher,Marius Stan,Stefan Kääb,Lars Kellert,Konstantinos Dimitriadis,Anna Kopczak,Bettina Küster,Moritz Sinner,Ignaz Steiger,Maria Kaffe,Sebastian Clauß,Daniel Janowitz,Raffael Thaler,Peter Schellinger,Jörg Glahn,Jan Schubert,Simone Jenniges,Silke Markmann-Boenke,Anne-Sophie Putzer,Michael Schwarze Vera Straeten,Marcus Wiemer,Kosmas Macha,David Haupenthal,Stefanie Balk,Clara-Sophie Kossel,Georg Häusler,Dominik Lehrieder,Peter Cidlinsky,Christian Hametner,Christine Vogl,Thomas Fischer,Moritz Huttelmaier,Octavian Maniuc Peter Nordbeck,Albrecht von Hardenberg,Martin Jünemann,Tobias Braun,Maxime Viard,Stefan Gerner,AlHaj Omar,Sonja Genau,Linus Olbricht,Matthias Wassenberg,Niklas Langguth,Christian Fräbel,Romy Baumgart,Love-Preet Kalra,Norma Diel,Frank Hoffmann,Bettine Schönmuth,Anja Giebler,Lorenz Weber,Jan Birringer,Sandra Lichte-Schneider,Daniela Hütwohl,Lars Udo Krause,Martina Petersen,Konstantin Kirchmeier,Liubov Novikova,Susanne Müller,Sebastian Schellong,Mirko Brudzinski,Ulrich Gerk,Holger Palisch,Frank R Heinzel,Jana Fett,Avinash Suntha,Katja Burian,Bettina Schmitz,Anna Gutwinski,Veronika Angermüller,Tameem Alhammoud,Hüsniye Cakiroglu,Ullrich Bach,Darius Nabavi,Jens Offermann,Olaf Crome,Boris Dimitrijeski,Carsten Meincke,Gerhard Hamann,Burkhard Alber,Robert Müller,Lars-Peder Pallesen,Volker Pütz,Christian Hartmann,Jörg Berrouschot,Anett Stoll,Janina Keilitz,Dietrich Klunk,Roman Voigt,Andreas Kastrup,Andreas Schröter,Johannes Schmucker,Waltraud Pfeilschifter,Christoffer Krämer,Milena Wiemers,Micha Simon,Alexander Finke,Christian Weiß,Carsten Hobohm,Katrin Naupold,Karen Bley-Renning,Sabrina Winter,Sven Poli,Annerose Mengel,Khouloud Poli,Alexandra Gómez Expósito,Joshua Mbroh,Maria Tieck,Michael Rosenkranz,Stefan Boskamp,Nicolas Ritter,Lena Seibel,Christian Schöps,Rebecca Ketzler,Herbert Nägele,Karsten Sydow,Natalia Kurka,Jan Hendrik Schäfer,Daniel Charisse,Katharina Gruber,Konstantin Kohlhase,Franziska Lieschke,Felix Operhalski,Alexander Seiler,Gabor Petzold,Felix Jürgen Bode,Sebastian Stösser,Julius Meißner,Taraneh Ebrahimi,Julia Nordsiek,Niklas Beckonert,Karin Weissenborn,Gerrit Maximilian Große,Hans Worthmann,Ann-Katrin Hennemann,Svenja Jochmann,Julius Gründahl,Jana Al-Ayoubi,Johanna Ernst,Oliver Bähr,Herbert Gruber,Sonka Benesch,Thomas Pollinger,Nawar Alachkar,Sonia Busch,Steffi Butz,Mathias Forkmann,Christian Mahnkopf,Thomas Mischke,Steffen Schnupp,Götz Thomalla,Milani Deb-Chatterji,Bastian Cheng,Mathias Gelderblom,Julia Hoppe,Märit Jensen,Maximilian Schell,Eckhard Schlemm,Lars Marquardt,Haiko Kazarians,Pia Franziska Rheingans,Kai Hötzer,Dietmar Rose,Tobias Neumann-Haefelin,Jörg Berthel,Lirim Alijaj,Joachim Krug,Margit Niethammer,Géza-Attila Szöllösi,Marc Obermann,Nicoletta Adochitei,Herwig Strik,Arne Lenz,Frank Steigerwald,Jörg Müller,Martin Honermann,Marian Christoph Burgstaller,Rainer Kollmar,Maryam Rashid,Ahmad Ajaz Ganai,Ossendorf,Majda Saric,Karl-Heinz Tischer,Adela Toluli,Frank Arne Wollenweber,Laya Rahban,Thais Portugal Silva,Miri Lee,Matthias Julius Grosch,Jens Minnerup,Jan Liman,Martin Nückel,Magdalena Böhm

DOI: https://doi.org/10.1016/j.ahj.2023.06.016

Abstract:Background: Atrial fibrillation (AF) is one of the most frequent causes of stroke. Several randomized trials have shown that prolonged monitoring increases the detection of AF, but the effect on reducing recurrent cardioembolism, ie, ischemic stroke and systemic embolism, remains unknown. We aim to evaluate whether a risk-adapted, intensified heart rhythm monitoring with consequent guideline conform treatment, which implies initiation of oral anticoagulation (OAC), leads to a reduction of recurrent cardioembolism. Methods: Find-AF 2 is a randomized, controlled, open-label parallel multicenter trial with blinded endpoint assessment. 5,200 patients ≥ 60 years of age with symptomatic ischemic stroke within the last 30 days and without known AF will be included at 52 study centers with a specialized stroke unit in Germany. Patients without AF in an additional 24-hour Holter ECG after the qualifying event will be randomized in a 1:1 fashion to either enhanced, prolonged and intensified ECG-monitoring (intervention arm) or standard of care monitoring (control arm). In the intervention arm, patients with a high risk of underlying AF will receive continuous rhythm monitoring using an implantable cardiac monitor (ICM) whereas those without high risk of underlying AF will receive repeated 7-day Holter ECGs. The duration of rhythm monitoring within the control arm is up to the discretion of the participating centers and is allowed for up to 7 days. Patients will be followed for at least 24 months. The primary efficacy endpoint is the time until recurrent ischemic stroke or systemic embolism occur. Conclusions: The Find-AF 2 trial aims to demonstrate that enhanced, prolonged and intensified rhythm monitoring results in a more effective prevention of recurrent ischemic stroke and systemic embolism compared to usual care.
Long-term health sequelae and quality of life at least 6 months after infection with SARS-CoV-2: design and rationale of the COVIDOM-study as part of the NAPKON population-based cohort platform (POP)

A. Horn,L. Krist,W. Lieb,F. A. Montellano,M. Kohls,K. Haas,G. Gelbrich,S. J. Bolay-Gehrig,C. Morbach,J. P. Reese,S. Störk,J. Fricke,T. Zoller,S. Schmidt,P. Triller,L. Kretzler,M. Rönnefarth,C. Von Kalle,S. N. Willich,F. Kurth,F. Steinbeis,M. Witzenrath,T. Bahmer,A. Hermes,M. Krawczak,L. Reinke,C. Maetzler,J. Franzenburg,J. Enderle,A. Flinspach,J. Vehreschild,M. Schons,T. Illig,G. Anton,K. Ungethüm,B. C. Finkenberg,M. T. Gehrig,N. Savaskan,P. U. Heuschmann,T. Keil,S. Schreiber

DOI: https://doi.org/10.1007/s15010-021-01707-5

2021-10-12

Infection

Abstract:Abstract Purpose Over the course of COVID-19 pandemic, evidence has accumulated that SARS-CoV-2 infections may affect multiple organs and have serious clinical sequelae, but on-site clinical examinations with non-hospitalized samples are rare. We, therefore, aimed to systematically assess the long-term health status of samples of hospitalized and non-hospitalized SARS-CoV-2 infected individuals from three regions in Germany. Methods The present paper describes the COVIDOM-study within the population-based cohort platform (POP) which has been established under the auspices of the NAPKON infrastructure (German National Pandemic Cohort Network) of the national Network University Medicine (NUM). Comprehensive health assessments among SARS-CoV-2 infected individuals are conducted at least 6 months after the acute infection at the study sites Kiel, Würzburg and Berlin. Potential participants were identified and contacted via the local public health authorities, irrespective of the severity of the initial infection. A harmonized examination protocol has been implemented, consisting of detailed assessments of medical history, physical examinations, and the collection of multiple biosamples (e.g., serum, plasma, saliva, urine) for future analyses. In addition, patient-reported perception of the impact of local pandemic-related measures and infection on quality-of-life are obtained. Results As of July 2021, in total 6813 individuals infected in 2020 have been invited into the COVIDOM-study. Of these, about 36% wished to participate and 1295 have already been examined at least once. Conclusion NAPKON-POP COVIDOM-study complements other Long COVID studies assessing the long-term consequences of an infection with SARS-CoV-2 by providing detailed health data of population-based samples, including individuals with various degrees of disease severity. Trial registration Registered at the German registry for clinical studies (DRKS00023742).

infectious diseases
Clinical Effectiveness of Newborn Screening for Spinal Muscular Atrophy

Oliver Schwartz,Katharina Vill,Michelle Pfaffenlehner,Max Behrens,Claudia Weiß,Jessika Johannsen,Johannes Friese,Andreas Hahn,Andreas Ziegler,Sabine Illsinger,Martin Smitka,Arpad von Moers,Heike Kölbel,Gudrun Schreiber,Nadja Kaiser,Ekkehard Wilichowski,Marina Flotats-Bastardas,Ralf A. Husain,Matthias Baumann,Cornelia Köhler,Regina Trollmann,Annette Schwerin-Nagel,Astrid Eisenkölbl,Mareike Schimmel,Martin Fleger,Birgit Kauffmann,Gert Wiegand,Manuela Baumgartner,Christian Rauscher,Sebahattin Cirak,Dieter Gläser,Günther Bernert,Tim Hagenacker,Susanne Goldbach,Kristina Probst-Schendzielorz,Hanns Lochmüller,Wolfgang Müller-Felber,Ulrike Schara-Schmidt,Maggie C. Walter,Janbernd Kirschner,Astrid Pechmann,Petra Baum,Moritz Metelmann,Fiona Zeiner,Wolfgang Löscher,Veronika Pilshofer,Kathrin Mörtlbauer,Elke Pernegger,Anna Elmecker,Tanja Neimair,Verena Angermair,Mika Rappold,Alexandra Ille,Magdalena Gosk - Tomek,Anna Wiesenhofer,Katia Vettori,Anna Hüpper,Theresa Stadler,Astrid Bertsche,Josefine Pauschek,Markus Blankenburg,Christof Reihle,Michael Schroth,Sarah Braun,Eva-Maria Wendel,Julia Haverkamp,Daniela Banholzer,Annette Karolin Homma,Jonas Denecke,Joenna Driemeyer,Deike Weiss,Paula-Sophie Steffens,Jila Taherpour,Marcus Deschauer,Paul Lingor,Luisa Semmler,Gerrit Machetanz,Matthias Eckenweiler,Bettina Henzi,Cornelia Müller,Thorsten Langer,Sabine Wider,Juliane Hug,Sabine Stein,Sibylle Vogt,Katharina Dörnbrack,Christina Saier,Adrian Tassoni,Franziska Wenzel,Tim Kampowski,Axel Gebert,Elisabeth Steiner,Manuel Pühringer,Sandra Baumann,Andrea Dall,Christina Bant,Tabea Reinhardt,Michael Zemlin,Sabine Hettrich,Dorothea Holzwarth,Stephanie Geitmann,Gabriel Dworschak,Franziska Busch,Ute Baur,Marion Richmann,Tobias Geis,Wolfgang Wittmann,Klaus Goldhahn,Manuela Theophil,Arpad von Moers,Katharina Müller-Kaempffer,Daniela Zeisler,Kathrin Bühner,Sylke Nicolai,Martin Groß,Stefan Kappel,René Günther,Maren Freigang,Hanna Sophie Lapp,Isabelle Dittes,Maria Wessel,Benjamin Stolte,Svenja Brakemeier,Andreas Thimm,Jaqueline Lipka,Melina Schlag,Kyriakos Martakis,Tascha Gehrke,Lisa Quinten,Andrea Hackemer,Lena Ruß,Omar Atta,Annina Lang,Eckard Hamelmann,Georg Classen,Klearchos Ntemiris,Kristina Albers,Loreen Plugge,Veronka Horber,Doris Roland-Schäfer,Andrea Bevot,Eva Jansen,Hanna Küpper,Birgit Meßmer,Daniela Steuernagel,Sabine Borowski,Christa Bretschneider,Erdmute Roth,Anja Müller,Heike de Vries,Hans Hartmann,Barbara Ramadan,Christoph Kamm,Sophie Fischer,Marieke Wermuth,Ulf Hustedt,Jan Christoph Koch,Mohamad Tareq Muhandes,Tobias Baum,Anna Hotter,Albert Ludolph,Zeljko Uzelac,Simon Witzel,Johannes Dorst,Joachim Schuster,Kurt Wollinsky,Pascal Martin,Alexander Mensch,Steffen Naegel,Ilka Schneider,Thomas Kendzierski,Anna Koelsch,Gerd Meyer zu Hörste,Sarah Wiethoff,Esra Akova-Oztürk,Astrid Blaschek,Iris Hannibal,Birgit Warken-Madelung,Therese Well,Elisabeth Rotenfusser,Maren Nitzsche,Christoph Neuwirth,Nathalie Braun,Zylfie Dibrani,Jasmin Bischofberger,Susanne Petri,Bogdan Bjelica,Camilla Wohnrade,Tilman Riesmeier,Michaela Schwippert,Antonia Leinert,Alma Oscmanovic,Olivia Schreiber-Katz,Astrid Eisenkölbl,Imke Rathmann,Dorothee Schäfer,Adela Della-Marina,Andrea Gangfuß,Britta Holtkamp,Barbara Andres,Isabelle Renger,Daniela Angelova-Toshkina,Lisa Jung,Bertold Schrank,Bernd Wilken,Alma Osmanovic,Barbara Fiedler,Timo Deba,Eva Johann to Settel,Katja Köbbing,Heymut Omran,Hélène Guillemot,Barbara Plecko,Joachim Zobel,Michael Grässl,Sander Claeys,Maja von der Hagen,Jens Schallner,Susan Fiebig,Sandy Foerster,Nicole Claus,Ilka Lehnert,Julie Hammer,Meike Steinbach,Maike Tomforde,Johannes Stoffels,Thomas Voelkl,Christina Kraut,Carmen Hollerauer,Lea Seeber,Mike Grünwedel,Raffi Topakian,Petra Müller,Peter Vollmann,Ina Krahwinkler,Bettina Behring,Stephanie Schüssler,Matthias Türk,Matthias Vorgerd,Anne Güttsches,Melanie Roeder,Irene Lange,Peter Reilich,Miriam Hiebeler,Federica Montagnese,Simone Thiele,Anna Hagenmeyer,Laura Grimm,Corinna Wirner-Piotrowski,Markus Weiler,Wolfgang Wick,Nicole Berberich,Marcel Mann-Richter,Heidi Rochau-Trumpp,Marion Schnurr,Guido Stocker,Corinna Stoltenburg,Joanna Schneider,Alexandra Wagner,Annette George,Vladimir Dukic,Angela M. Kaindl,Lieske van der Stam,Gilbert Wunderlich,Claudia Diana Wurster*,Johannes Dorst*,Joachim Schuster*,Albert Christian Ludolph*,Daniel Zeller,Julia Bellut,Brigitte Brauner,Christine Leypold,Georg Friedrich Hoffmann,Stefan Kölker,Afshin Saffari,Moritz Niesert,Sabine Specht,Annegret Hoevel,Anke Bongartz,Daniela Zöller,Harald Binder,Maren Hackenberg,

DOI: https://doi.org/10.1001/jamapediatrics.2024.0492

2024-04-08

JAMA Pediatrics

Abstract:Importance There is increasing evidence that early diagnosis and treatment are key for outcomes in infants with spinal muscular atrophy (SMA), and newborn screening programs have been implemented to detect the disease before onset of symptoms. However, data from controlled studies that reliably confirm the benefits of newborn screening are lacking. Objective To compare data obtained on patients with SMA diagnosed through newborn screening and those diagnosed after clinical symptom onset. Design, Setting, and Participants This nonrandomized controlled trial used data from the SMARTCARE registry to evaluate all children born between January 2018 and September 2021 with genetically confirmed SMA and up to 3 SMN2 copies. The registry includes data from 70 participating centers in Germany, Austria, and Switzerland. Data analysis was performed in February 2023 so that all patients had a minimal follow-up of 18 months. Exposure Patients born in 2 federal states in Germany underwent screening in a newborn screening pilot project. All other patients were diagnosed after clinical symptom onset. All patients received standard care within the same health care system. Main Outcomes The primary end point was the achievement of motor milestones. Results A total of 234 children (123 [52.6%] female) were identified who met inclusion criteria and were included in the analysis: 44 (18.8%) in the newborn screening cohort and 190 children (81.2%) in the clinical symptom onset cohort. The mean (SD) age at start of treatment with 1 of the approved disease-modifying drugs was 1.3 (2.2) months in the newborn screening cohort and 10.7 (9.1) months in the clinical symptom onset cohort. In the newborn screening cohort, 40 of 44 children (90.9%) gained the ability to sit independently vs 141 of 190 (74.2%) in the clinical symptom onset cohort. For independent ambulation, the ratio was 28 of 40 (63.6%) vs 28 of 190 (14.7%). Conclusions and Relevance This nonrandomized controlled trial demonstrated effectiveness of newborn screening for infants with SMA in the real-world setting. Functional outcomes and thus the response to treatment were significantly better in the newborn screening cohort compared to the unscreened clinical symptom onset group. Trial Registration German Clinical Trials Register: DRKS00012699

pediatrics
Phenotypes of disease severity in a cohort of hospitalized COVID-19 patients: Results from the IMPACC study

Al Ozonoff,Joanna Schaenman,Naresh Doni Jayavelu,Carly E. Milliren,Carolyn S. Calfee,Charles B. Cairns,Monica Kraft,Lindsey R. Baden,Albert C. Shaw,Florian Krammer,Harm van Bakel,Denise A. Esserman,Shanshan Liu,Ana Fernandez Sesma,Viviana Simon,David A. Hafler,Ruth R. Montgomery,Steven H. Kleinstein,Ofer Levy,Christian Bime,Elias K. Haddad,David J. Erle,Bali Pulendran,Kari C. Nadeau,Mark M. Davis,Catherine L. Hough,William B. Messer,Nelson I. Agudelo Higuita,Jordan P. Metcalf,Mark A. Atkinson,Scott C. Brakenridge,David Corry,Farrah Kheradmand,Lauren I.R. Ehrlich,Esther Melamed,Grace A. McComsey,Rafick Sekaly,Joann Diray-Arce,Bjoern Peters,Alison D. Augustine,Elaine F. Reed,Matthew C. Altman,Patrice M. Becker,Nadine Rouphael,Al Ozonoff,Joanna Schaenman,Naresh Doni Jayavelu,Carly E. Milliren,Carolyn S. Calfee,Charles B. Cairns,Monica Kraft,Lindsey R. Baden,Albert C. Shaw,Florian Krammer,Harm van Bakel,Denise A. Esserman,Shanshan Liu,Ana Fernandez Sesma,Viviana Simon,David A. Hafler,Ruth R. Montgomery,Steven H. Kleinstein,Ofer Levy,Chris Bime,Elias K. Haddad,David J. Erle,Bali Pulendran,Kari C. Nadeau,Mark M Davis,Catherine L. Hough,William B. Messer,Nelson I. Agudelo Higuita,Jordan P. Metcalf,Mark A. Atkinson,Scott C. Brakenridge,David Corry,Farrah Kheradmand,Lauren I.R. Ehrlich,Esther Melamed,Grace A. McComsey,Rafick Sekaly,Joann Diray-Arce,Bjoern Peters,Alison D. Augustine,Elaine F. Reed,Kerry McEnaney,Brenda Barton,Claudia Lentucci,Mehmet Saluvan,Ana C. Chang,Annmarie Hoch,Marisa Albert,Tanzia Shaheen,Alvin T. Kho,Sanya Thomas,Jing Chen,Maimouna D. Murphy,Mitchell Cooney,Scott Presnell,Gabriela K. Fragiadakis,Ravi Patel,Leying Guan,Jeremy Gygi,Shrikant Pawar,Anderson Brito,Zain Khalil,Cole Maguire,Slim Fourati,James A. Overton,Randi Vita,Kerstin Westendorf,Ramin Salehi-Rad,Aleksandra Leligdowicz,Michael A. Matthay,Jonathan P. Singer,Kirsten N. Kangelaris,Carolyn M. Hendrickson,Matthew F. Krummel,Charles R. Langelier,Prescott G. Woodruff,Debra L. Powell,James N. Kim,Brent Simmons,I. Michael Goonewardene,Cecilia M. Smith,Mark Martens,Jarrod Mosier,Hiroki Kimura,Amy C. Sherman,Stephen R. Walsh,Nicolas C. Issa,Charles Dela Cruz,Shelli Farhadian,Akiko Iwasaki,Albert I. Ko,Sharon Chinthrajah,Neera Ahuja,Angela J. Rogers,Maja Artandi,Sarah A.R. Siegel,Zhengchun Lu,Douglas A. Drevets,Brent R. Brown,Matthew L. Anderson,Faheem W. Guirgis,Rama V. Thyagarajan,Justin F. Rousseau,Dennis Wylie,Johanna Busch,Saurin Gandhi,Todd A. Triplett,George Yendewa,Olivia Giddings,Evan J. Anderson,Aneesh K. Mehta,Jonathan E. Sevransky,Bernard Khor,Adeeb Rahman,Daniel Stadlbauer,Jayeeta Dutta,Hui Xie,Seunghee Kim-Schulze,Ana Silvia Gonzalez-Reiche,Adriana van de Guchte,Keith Farrugia,Zenab Khan,Holden T. Maecker,David Elashoff,Jenny Brook,Estefania Ramires-Sanchez,Megan Llamas,Adreanne Rivera,Claudia Perdomo,Dawn C. Ward,Clara E. Magyar,Jennifer A. Fulcher,Yumiko Abe-Jones,Saurabh Asthana,Alexander Beagle,Sharvari Bhide,Sidney A. Carrillo,Suzanna Chak,Gabriela K. Fragiadakis,Rajani Ghale,Ana Gonzalez,Alejandra Jauregui,Norman Jones,Tasha Lea,Deanna Lee,Raphael Lota,Jeff Milush,Viet Nguyen,Logan Pierce,Priya A. Prasad,Arjun Rao,Bushra Samad,Cole Shaw,Austin Sigman,Pratik Sinha,Alyssa Ward,Andrew Willmore,Jenny Zhan,Sadeed Rashid,Nicklaus Rodriguez,Kevin Tang,Luz Torres Altamirano,Legna Betancourt,Cindy Curiel,Nicole Sutter,Maria Tercero Paz,Gayelan Tietje-Ulrich,Carolyn Leroux,Jennifer Connors,Mariana Bernui,Michel A. Kutzler,Carolyn Edwards,Edward Lee,Edward Lin,Brett Croen,Nicholas C. Semenza,Brandon Rogowski,Nataliya Melnyk,Kyra Woloszczuk,Gina Cusimano,Mathew R. Bell,Sara Furukawa,Renee McLin,Pamela Marrero,Julie Sheidy,George P. Tegos,Crystal Nagle,Nathan Mege,Kristen Ulring,Vicki Seyfert-Margolis,Michelle Conway,Dave Francisco,Allyson Molzahn,Heidi Erickson,Connie Cathleen Wilson,Ron Schunk,Bianca Sierra,Trina Hughes,Kinga Smolen,Michael Desjardins,Simon van Haren,Xhoi Mitre,Jessica Cauley,Xiaofang Li,Alexandra Tong,Bethany Evans,Christina Montesano,Jose Humberto Licona,Jonathan Krauss,Jun Bai Park Chang,Natalie Izaguirre,Omkar Chaudhary,Andreas Coppi,John Fournier,Subhasis Mohanty,M. Catherine Muenker,Allison Nelson,Khadir Raddassi,Michael Rainone,William E. Ruff,Syim Salahuddin,Wade L. Schulz,Pavithra Vijayakumar,Haowei Wang,H. Patrick Young,Yujiao Zhao,Miti Saksena,Deena Altman,Erna Kojic,Komal Srivastava,Lily Q. Eaker,Maria C. Bermúdez-González,Katherine F. Beach,Levy A. Sominsky,Arman R. Azad,Juan Manuel Carreño,Gagandeep Singh,Ariel Raskin,Johnstone Tcheou,Dominika Bielak,Hisaaki Kawabata,Lubbertus CF Mulder,Giulio Kleiner,Alexandra S. Lee,Andrea Fernandes,Monali Manohar,Thomas Hagan,Catherine A. Blish,Hena Naz Din,Jonasel Roque,Samuel Yang,Amanda Brunton,Peter E. Sullivan,Matthew Strnad,Zoe L. Lyski,Felicity J. Coulter,J. Leland Booth,Lauren A. Sinko,Lyle L. Moldawer,Brittany Borresen,Brittney Roth-Manning,Li-Zhen Song,Ebony Nelson,Megan Lewis-Smith,Jacob Smith,Pablo Guaman Tipan,Nadia Siles,Sam Bazzi,Janelle Geltman,Kerin Hurley,Gio Gabriele,Scott Sieg,Tatyana Vaysman,Laurel Bristow,Laila Hussaini,Kieffer Hellmeister,Hady Samaha,Andrew Cheng,Christine Spainhour,Erin M. Scherer,Brandi Johnson,Amer Bechnak,Caroline R. Ciric,Lauren Hewitt,Erin Carter,Nina Mcnair,Bernadine Panganiban,Christopher Huerta,Jacob Usher,Susan Pereira Ribeiro,Matthew C. Altman,Patrice M. Becker,Nadine Rouphael,Elsio Wunder Jr.,Evan Do Do

DOI: https://doi.org/10.1016/j.ebiom.2022.104208

IF: 11.205

2022-09-01

EBioMedicine

Abstract:BACKGROUND: Better understanding of the association between characteristics of patients hospitalized with coronavirus disease 2019 (COVID-19) and outcome is needed to further improve upon patient management.METHODS: Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC) is a prospective, observational study of 1164 patients from 20 hospitals across the United States. Disease severity was assessed using a 7-point ordinal scale based on degree of respiratory illness. Patients were prospectively surveyed for 1 year after discharge for post-acute sequalae of COVID-19 (PASC) through quarterly surveys. Demographics, comorbidities, radiographic findings, clinical laboratory values, SARS-CoV-2 PCR and serology were captured over a 28-day period. Multivariable logistic regression was performed.FINDINGS: The median age was 59 years (interquartile range [IQR] 20); 711 (61%) were men; overall mortality was 14%, and 228 (20%) required invasive mechanical ventilation. Unsupervised clustering of ordinal score over time revealed distinct disease course trajectories. Risk factors associated with prolonged hospitalization or death by day 28 included age ≥ 65 years (odds ratio [OR], 2.01; 95% CI 1.28-3.17), Hispanic ethnicity (OR, 1.71; 95% CI 1.13-2.57), elevated baseline creatinine (OR 2.80; 95% CI 1.63- 4.80) or troponin (OR 1.89; 95% 1.03-3.47), baseline lymphopenia (OR 2.19; 95% CI 1.61-2.97), presence of infiltrate by chest imaging (OR 3.16; 95% CI 1.96-5.10), and high SARS-CoV2 viral load (OR 1.53; 95% CI 1.17-2.00). Fatal cases had the lowest ratio of SARS-CoV-2 antibody to viral load levels compared to other trajectories over time (p=0.001). 589 survivors (51%) completed at least one survey at follow-up with 305 (52%) having at least one symptom consistent with PASC, most commonly dyspnea (56% among symptomatic patients). Female sex was the only associated risk factor for PASC.INTERPRETATION: Integration of PCR cycle threshold, and antibody values with demographics, comorbidities, and laboratory/radiographic findings identified risk factors for 28-day outcome severity, though only female sex was associated with PASC. Longitudinal clinical phenotyping offers important insights, and provides a framework for immunophenotyping for acute and long COVID-19.FUNDING: NIH.

medicine, research & experimental
Characterising HIV-Indicator conditions among two nationwide long-term cohorts of people living with HIV in Germany (1999–2023)

Amrei Krings,Christian Kollan,Daniel Schmidt,Barbara Gunsenheimer-Bartmeyer,Frederik Valbert,Anja Neumann,Jürgen Wasem,Georg M. N. Behrens,Markus Bickel,Christoph Boesecke,Stefan Esser,Patrik Dröge,Thomas Ruhnke,Uwe Koppe,the HIV-1 Seroconverter, ClinSurv-HIV study groups,Heribert Knechten,Petra Panstrugart,Keikawus Arasteh,Michael Rittweger,Hans Wesselmann,Nikolai Menner,Dirk Schürmann,Marianne Warncke,Ulrich Bohr,Heiko Jessen,Arne B. Jessen,Hubert Schulbin,Sascha Brand,Jan Gumprecht,Beate Weninger,Heribert Hillenbrand,Heiko Karcher,Klaus Fischer,Dietmar Schranz,Mathias Vallée,Jukka Hartikainen,Stephan Grunwald,Jörg A. Claus,Claudia Thomas,Roland Grimm,Sarah Schoor,Christiane Cordes,Reinhold Schröder,Tobias Glaunsinger,Michael Rausch,Thomas Reineke,Gordon Weinberg,Manuel Bruhy,Siegfried Köppe,Peter Kreckel,Andreas Berger,Sinah Lindemann,Norbert H. Brockmeyer,Anja Potthoff,Kathrin van Bremen,Jürgen Rockstroh,Jan-Christian Wasmuth,Svetlana Hass,Martin Hower,Claudia Bachmann,Petra Spornraft-Ragaller,Dieter Teichmann,Björn-Erik Ole Jensen,Falk Hüttig,Cecilie Feind,Pia Schenk-Westkamp,Annette Haberl,Christoph Stephan,Peter Schott,Susanne Usadel,Matthias Müller,Janina Trauth,Alan Chavez-Valladares,Gerd Deutschinoff,Burkhard Kreft,Danica Lange,Olaf Degen,Guido Schäfer,Andreas Plettenberg,Frieder Kuhlendahl,Thore Lorenzen,Dorothea Wiemer,Lavinia Biemann,Axel Adam,Thomas Buhk,Stephan Fenske,Stefan Hansen,Michael Sabranski,Knud Schewe,Christian Hoffmann,Hans-Jürgen Stellbrink,Dennis Radzuweit,Alexander Mainka,Constantin Rickassel,Olaf Degen,Guido Schäfer,Robin Scheiter,Georg Behrens,Matthias Stoll,Steve Gerschmann,Renate Beider,Benjamin T. Schleenvoigt,Mathias W. Pletz,Heinz-August Horst,Silke Trautmann,Ansgar Rieke,Stephan Schneeweiß,Stefan Scholten,Mark Oette,Gerd Fätkenheuer,Jörg Janne Vehreschild,Laura Hamacher,Lennart Nicksch,Peter A. Arbter,Thomas Grünewald,Jeannine Weidemann,Ines Ruck,Bernd Claus,Martin Sprinzl,Peter R. Galle,Matthias P. Ebert,Roger Vogelmann,Johannes Bogner,Ulrike Hellerer,Barbara Sonntag,Oliver Pullen,Antoniya Todorova,Claudia Traidl-Hoffmann,Birgit Mück,Ramona Pauli,Christoph D. Spinner,Jochen Schneider,Birgit Mück,Robert Baumann,Niels Schübel,Christiane Berning,Franz Audebert,Carlos Fritzsche,A Trein,E Schnaitmann,Clemens Roll,Simone Marquardt,Georg Härter,Beate Grüner,Cengiz Güler,Steve Rößler

DOI: https://doi.org/10.1007/s15010-024-02419-2

2024-11-01

Infection

Abstract:Background/Objective Information about occurrence and affected groups of symptoms/diagnoses indicative of an HIV infection (so-called HIV indicator conditions; HIV-ICs) is lacking. We analyse HIV-IC incidence, transmission risks and immune status among people living with HIV (PLWH) antiretroviral therapy (ART) naive. Methods Diagnoses reported for ART-naive PLWH from two multicentre observational, prospective cohort studies between 1999–2023 were analysed. Incidence rates per 1,000 person-years (PYs) were calculated for the overall study period and time periods defined by ART treatment recommendations. For further description, CD4 counts around HIV-IC diagnosis (+ -30 days) and HIV-transmission routes were collected. Results In total 15,940 diagnoses of 18,534 PLWH in Germany were included. Of those 81% were male (median age: 36 years) and 56% reported being men, who have sex with men as the likely HIV-transmission route. Incidence rates varied between the different HIV-ICs. Syphilis had the highest incidence rate (34 per 1,000 PYs; 95% confidence interval [CI] 29–40) for sexually transmitted infections (STIs), hepatitis B was highest for viral hepatitis diagnoses (18 per 1,000 PYs; 95% CI 17–20); according to CDC-classification herpes zoster for HIV-associated diagnoses (22 per 1,000; 95% CI 20–24) and candidiasis for AIDS-defining diagnoses (30 per 1,000 PYs; 95% CI 29–32). Most PLWH with HIV-ICs (hepatitis, HIV-associated diagnoses and AIDS-defining conditions) had CD4 cell counts < 350. Conclusion This analysis characterizes HIV-ICs regarding the incidence, HIV-transmission route and patients' immune status. The results underline the importance of HIV-IC-based screening to detect PLWH with already partially impaired immune status and in need of timely ART initiation.

infectious diseases
Anonymity in Attribute-Based Group Signatures

Bhumika K. Patel,D. Jinwala

DOI: https://doi.org/10.1007/978-3-642-29280-4_58

2011-12-16

Abstract:
Researching COVID to Enhance Recovery (RECOVER) adult study protocol: Rationale, objectives, and design

Leora I Horwitz,Tanayott Thaweethai,Shari B Brosnahan,Mine S Cicek,Megan L Fitzgerald,Jason D Goldman,Rachel Hess,S L Hodder,Vanessa L Jacoby,Michael R Jordan,Jerry A Krishnan,Adeyinka O Laiyemo,Torri D Metz,Lauren Nichols,Rachel E Patzer,Anisha Sekar,Nora G Singer,Lauren E Stiles,Barbara S Taylor,Shifa Ahmed,Heather A Algren,Khamal Anglin,Lisa Aponte-Soto,Hassan Ashktorab,Ingrid V Bassett,Brahmchetna Bedi,Nahid Bhadelia,Christian Bime,Marie-Abele C Bind,Lora J Black,Andra L Blomkalns,Hassan Brim,Mario Castro,James Chan,Alexander W Charney,Benjamin K Chen,Li Qing Chen,Peter Chen,David Chestek,Lori B Chibnik,Dominic C Chow,Helen Y Chu,Rebecca G Clifton,Shelby Collins,Maged M Costantine,Sushma K Cribbs,Steven G Deeks,John D Dickinson,Sarah E Donohue,Matthew S Durstenfeld,Ivette F Emery,Kristine M Erlandson,Julio C Facelli,Rachael Farah-Abraham,Aloke V Finn,Melinda S Fischer,Valerie J Flaherman,Judes Fleurimont,Vivian Fonseca,Emily J Gallagher,Jennifer C Gander,Maria Laura Gennaro,Kelly S Gibson,Minjoung Go,Steven N Goodman,Joey P Granger,Frank L Greenway,John W Hafner,Jenny E Han,Michelle S Harkins,Kristine S P Hauser,James R Heath,Carla R Hernandez,On Ho,Matthew K Hoffman,Susan E Hoover,Carol R Horowitz,Harvey Hsu,Priscilla Y Hsue,Brenna L Hughes,Prasanna Jagannathan,Judith A James,Janice John,Sarah Jolley,S E Judd,Joy J Juskowich,Diane G Kanjilal,Elizabeth W Karlson,Stuart D Katz,J Daniel Kelly,Sara W Kelly,Arthur Y Kim,John P Kirwan,Kenneth S Knox,Andre Kumar,Michelle F Lamendola-Essel,Margaret Lanca,Joyce K Lee-Lannotti,R Craig Lefebvre,Bruce D Levy,Janet Y Lin,Brian P Logarbo,Jennifer K Logue,Michele T Longo,Carlos A Luciano,Karen Lutrick,Shahdi K Malakooti,Gail Mallett,Gabrielle Maranga,Jai G Marathe,Vincent C Marconi,Gailen D Marshall,Christopher F Martin,Jeffrey N Martin,Heidi T May,Grace A McComsey,Dylan McDonald,Hector Mendez-Figueroa,Lucio Miele,Murray A Mittleman,Sindhu Mohandas,Christian Mouchati,Janet M Mullington,Girish N Nadkarni,Erica R Nahin,Robert B Neuman,Lisa T Newman,Amber Nguyen,Janko Z Nikolich,Igho Ofotokun,Princess U Ogbogu,Anna Palatnik,Kristy T S Palomares,Tanyalak Parimon,Samuel Parry,Sairam Parthasarathy,Thomas F Patterson,Ann Pearman,Michael J Peluso,Priscilla Pemu,Christian M Pettker,Beth A Plunkett,Kristen Pogreba-Brown,Athena Poppas,J Zachary Porterfield,John G Quigley,Davin K Quinn,Hengameh Raissy,Candida J Rebello,Uma M Reddy,Rebecca Reece,Harrison T Reeder,Franz P Rischard,Johana M Rosas,Clifford J Rosen,Nadine G Rouphael,Dwight J Rouse,Adam M Ruff,Christina Saint Jean,Grecio J Sandoval,Jorge L Santana,Shannon M Schlater,Frank C Sciurba,Caitlin Selvaggi,Sudha Seshadri,Howard D Sesso,Dimpy P Shah,Eyal Shemesh,Zaki A Sherif,Daniel J Shinnick,Hyagriv N Simhan,Upinder Singh,Amber Sowles,Vignesh Subbian,Jun Sun,Mehul S Suthar,Larissa J Teunis,John M Thorp,Amberly Ticotsky,Alan T N Tita,Robin Tragus,Katherine R Tuttle,Alfredo E Urdaneta,P J Utz,Timothy M VanWagoner,Andrew Vasey,Suzanne D Vernon,Crystal Vidal,Tiffany Walker,Honorine D Ward,David E Warren,Ryan M Weeks,Steven J Weiner,Jordan C Weyer,Jennifer L Wheeler,Sidney W Whiteheart,Zanthia Wiley,Natasha J Williams,Juan P Wisnivesky,John C Wood,Lynn M Yee,Natalie M Young,Sokratis N Zisis,Andrea S Foulkes,Leora I. Horwitz,Shari B. Brosnahan,Mine S. Cicek,Megan L. Fitzgerald,Jason D. Goldman,S. L. Hodder,Vanessa L. Jacoby,Michael R. Jordan,Jerry A. Krishnan,Adeyinka O. Laiyemo,Torri D. Metz,Rachel E. Patzer,Nora G. Singer,Lauren E. Stiles,Barbara S. Taylor,Heather A. Algren,Ingrid V. Bassett,Marie-Abele C. Bind,Lora J. Black,Andra L. Blomkalns,Alexander W. Charney,Benjamin K. Chen,Lori B. Chibnik,Dominic C. Chow,Helen Y. Chu,Rebecca G. Clifton,Maged M. Costantine,Sushma K. Cribbs,Steven G. Deeks,John D. Dickinson,Sarah E. Donohue,Matthew S. Durstenfeld,Ivette F. Emery,Kristine M. Erlandson,Julio C. Facelli,Aloke V. Finn,Melinda S. Fischer,Valerie J. Flaherman,Emily J. Gallagher,Jennifer C. Gander,Kelly S. Gibson,Steven N. Goodman,Joey P. Granger,Frank L. Greenway,John W. Hafner,Jenny E. Han,Michelle S. Harkins,Kristine S. P. Hauser,James R. Heath,Carla R. Hernandez,Matthew K. Hoffman,Susan E. Hoover,Carol R. Horowitz,Priscilla Y. Hsue,Brenna L. Hughes,Judith A. James,S. E. Judd,Joy J. Juskowich,Diane G. Kanjilal,Elizabeth W. Karlson,Stuart D. Katz,J. Daniel Kelly,Sara W. Kelly,Arthur Y. Kim,John P. Kirwan,Kenneth S. Knox,Michelle F. Lamendola-Essel,Joyce K. Lee-lannotti,R. Craig Lefebvre,Bruce D. Levy,Janet Y. Lin,Brian P. Logarbo,Jennifer K. Logue,Michele T. Longo,Carlos A. Luciano,Shahdi K. Malakooti,Jai G. Marathe,Vincent C. Marconi,Gailen D. Marshall,Christopher F. Martin,Jeffrey N. Martin,Heidi T. May,Grace A. McComsey,Murray A. Mittleman,Janet M. Mullington,Girish N. Nadkarni,Erica R. Nahin,Robert B. Neuman,Lisa T. Newman,Janko Z. Nikolich,Princess U. Ogbogu,Kristy T. S. Palomares,Thomas F. Patterson,Michael J. Peluso,Christian M. Pettker,Beth A. Plunkett,J. Zachary Porterfield,John G. Quigley,Davin K. Quinn,Candida J. Rebello,Uma M. Reddy,Harrison T. Reeder,Franz P. Rischard,Johana M. Rosas,Clifford J. Rosen,Nadine G. Rouphael,Dwight J. Rouse,Adam M. Ruff,Grecio J. Sandoval,Jorge L. Santana,Shannon M. Schlater,Frank C. Sciurba,Howard D. Sesso,Dimpy P. Shah,Zaki A. Sherif,Daniel J. Shinnick,Hyagriv N. Simhan,Mehul S. Suthar,Larissa J. Teunis,John M. Thorp,Alan T. N. Tita,Katherine R. Tuttle,Alfredo E. Urdaneta,P. J. Utz,Timothy M. VanWagoner,Suzanne D. Vernon,Honorine D. Ward,David E. Warren,Ryan M. Weeks,Steven J. Weiner,Jordan C. Weyer,Jennifer L. Wheeler,Sidney W. Whiteheart,Natasha J. Williams,Juan P. Wisnivesky,John C. Wood,Lynn M. Yee,Natalie M. Young,Sokratis N. Zisis,Andrea S. Foulkes

DOI: https://doi.org/10.1371/journal.pone.0286297

IF: 3.7

2023-06-23

PLoS ONE

Abstract:Importance SARS-CoV-2 infection can result in ongoing, relapsing, or new symptoms or other health effects after the acute phase of infection; termed post-acute sequelae of SARS-CoV-2 infection (PASC), or long COVID. The characteristics, prevalence, trajectory and mechanisms of PASC are ill-defined. The objectives of the Researching COVID to Enhance Recovery (RECOVER) Multi-site Observational Study of PASC in Adults (RECOVER-Adult) are to: (1) characterize PASC prevalence; (2) characterize the symptoms, organ dysfunction, natural history, and distinct phenotypes of PASC; (3) identify demographic, social and clinical risk factors for PASC onset and recovery; and (4) define the biological mechanisms underlying PASC pathogenesis. Methods RECOVER-Adult is a combined prospective/retrospective cohort currently planned to enroll 14,880 adults aged ≥18 years. Eligible participants either must meet WHO criteria for suspected, probable, or confirmed infection; or must have evidence of no prior infection. Recruitment occurs at 86 sites in 33 U.S. states, Washington, DC and Puerto Rico, via facility- and community-based outreach. Participants complete quarterly questionnaires about symptoms, social determinants, vaccination status, and interim SARS-CoV-2 infections. In addition, participants contribute biospecimens and undergo physical and laboratory examinations at approximately 0, 90 and 180 days from infection or negative test date, and yearly thereafter. Some participants undergo additional testing based on specific criteria or random sampling. Patient representatives provide input on all study processes. The primary study outcome is onset of PASC, measured by signs and symptoms. A paradigm for identifying PASC cases will be defined and updated using supervised and unsupervised learning approaches with cross-validation. Logistic regression and proportional hazards regression will be conducted to investigate associations between risk factors, onset, and resolution of PASC symptoms. Discussion RECOVER-Adult is the first national, prospective, longitudinal cohort of PASC among US adults. Results of this study are intended to inform public health, spur clinical trials, and expand treatment options. Registration NCT05172024 .

multidisciplinary sciences
The collaborative outcomes study on health and functioning during infection times in adults (COH-FIT-Adults): Design and methods of an international online survey targeting physical and mental health effects of the COVID-19 pandemic

Marco Solmi,Andrés Estradé,Trevor Thompson,Agorastos Agorastos,Joaquim Radua,Samuele Cortese,Elena Dragioti,Friedrich Leisch,Davy Vancampfort,Lau Caspar Thygesen,Harald Aschauer,Monika Schloegelhofer,Elena Akimova,Andres Schneeberger,Christian G Huber,Gregor Hasler,Philippe Conus,Kim Q Do Cuénod,Roland von Känel,Gonzalo Arrondo,Paolo Fusar-Poli,Philip Gorwood,Pierre-Michel Llorca,Marie-Odile Krebs,Elisabetta Scanferla,Taishiro Kishimoto,Golam Rabbani,Karolina Skonieczna-Żydecka,Paolo Brambilla,Angela Favaro,Akihiro Takamiya,Leonardo Zoccante,Marco Colizzi,Julie Bourgin,Karol Kamiński,Maryam Moghadasin,Soraya Seedat,Evan Matthews,John Wells,Emilia Vassilopoulou,Ary Gadelha,Kuan-Pin Su,Jun Soo Kwon,Minah Kim,Tae Young Lee,Oleg Papsuev,Denisa Manková,Andrea Boscutti,Cristiano Gerunda,Diego Saccon,Elena Righi,Francesco Monaco,Giovanni Croatto,Guido Cereda,Jacopo Demurtas,Natascia Brondino,Nicola Veronese,Paolo Enrico,Pierluigi Politi,Valentina Ciappolino,Andrea Pfennig,Andreas Bechdolf,Andreas Meyer-Lindenberg,Kai G Kahl,Katharina Domschke,Michael Bauer,Nikolaos Koutsouleris,Sibylle Winter,Stefan Borgwardt,Istvan Bitter,Judit Balazs,Pal Czobor,Zsolt Unoka,Dimitris Mavridis,Konstantinos Tsamakis,Vasilios P Bozikas,Chavit Tunvirachaisakul,Michael Maes,Teerayuth Rungnirundorn,Thitiporn Supasitthumrong,Ariful Haque,Andre R Brunoni,Carlos Gustavo Costardi,Felipe Barreto Schuch,Guilherme Polanczyk,Jhoanne Merlyn Luiz,Lais Fonseca,Luana V Aparicio,Samira S Valvassori,Merete Nordentoft,Per Vendsborg,Sofie Have Hoffmann,Jihed Sehli,Norman Sartorius,Sabina Heuss,Daniel Guinart,Jane Hamilton,John Kane,Jose Rubio,Michael Sand,Ai Koyanagi,Aleix Solanes,Alvaro Andreu-Bernabeu,Antonia San José Cáceres,Celso Arango,Covadonga M Díaz-Caneja,Diego Hidalgo-Mazzei,Eduard Vieta,Javier Gonzalez-Peñas,Lydia Fortea,Mara Parellada,Miquel A Fullana,Norma Verdolini,Eva Fárková,Karolina Janků,Mark Millan,Mihaela Honciuc,Anna Moniuszko-Malinowska,Igor Łoniewski,Jerzy Samochowiec,Łukasz Kiszkiel,Maria Marlicz,Paweł Sowa,Wojciech Marlicz,Georgina Spies,Brendon Stubbs,Joseph Firth,Sarah Sullivan,Asli Enez Darcin,Hatice Aksu,Nesrin Dilbaz,Onur Noyan,Momoko Kitazawa,Shunya Kurokawa,Yuki Tazawa,Alejandro Anselmi,Cecilia Cracco,Ana Inés Machado,Natalia Estrade,Diego De Leo,Jackie Curtis,Michael Berk,Philip Ward,Scott Teasdale,Simon Rosenbaum,Wolfgang Marx,Adrian Vasile Horodnic,Liviu Oprea,Ovidiu Alexinschi,Petru Ifteni,Serban Turliuc,Tudor Ciuhodaru,Alexandra Bolos,Valentin Matei,Dorien H Nieman,Iris Sommer,Jim van Os,Therese van Amelsvoort,Ching-Fang Sun,Ta-Wei Guu,Can Jiao,Jieting Zhang,Jialin Fan,Liye Zou,Xin Yu,Xinli Chi,Philippe de Timary,Ruud van Winke,Bernardo Ng,Edilberto Pena,Ramon Arellano,Raquel Roman,Thelma Sanchez,Larisa Movina,Pedro Morgado,Sofia Brissos,Oleg Aizberg,Anna Mosina,Damir Krinitski,James Mugisha,Dena Sadeghi-Bahmani,Masoud Sadeghi,Samira Hadi,Serge Brand,Antonia Errazuriz,Nicolas Crossley,Dragana Ignjatovic Ristic,Carlos López-Jaramillo,Dimitris Efthymiou,Praveenlal Kuttichira,Roy Abraham Kallivayalil,Afzal Javed,Muhammad Iqbal Afridi,Bawo James,Omonefe Joy Seb-Akahomen,Jess Fiedorowicz,Andre F Carvalho,Jeff Daskalakis,Lakshmi N Yatham,Lin Yang,Tarek Okasha,Aïcha Dahdouh,Björn Gerdle,Jari Tiihonen,Jae Il Shin,Jinhee Lee,Ahmed Mhalla,Lotfi Gaha,Takoua Brahim,Kuanysh Altynbekov,Nikolay Negay,Saltanat Nurmagambetova,Yasser Abu Jamei,Mark Weiser,Christoph U Correll,Christian G. Huber,Kim Q. Do Cuénod,Kai G. Kahl,Vasilios P. Bozikas,Andre R. Brunoni,Luana V. Aparicio,Samira S. Valvassori,Covadonga M. Díaz-Caneja,Miquel A. Fullana,Dorien H. Nieman,Ta-wei Guu,Andre F. Carvalho,Lakshmi N. Yatham,Christoph U. Correll

DOI: https://doi.org/10.1016/j.jad.2021.07.048

IF: 6.533

2022-02-01

Journal of Affective Disorders

Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background</h3><p>: High-quality comprehensive data on short-/long-term physical/mental health effects of the COVID-19 pandemic are needed.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>: The Collaborative Outcomes study on Health and Functioning during Infection Times (COH-FIT) is an international, multi-language (n=30) project involving >220 investigators from 49 countries, endorsed by national/international professional associations. COH-FIT is a multi-wave, on-line anonymous, cross-sectional survey [wave 1: 04/2020 until the end of the pandemic, waves 2/3 starting 6/24 months threreafter] for adults, adolescents (14-17), and children (6-13), utilizing non-probability/snowball and representative sampling. COH-FIT aims to identify non-modifiable/modifiable risk factors/treatment targets to inform prevention/intervention programs to improve social/health outcomes in the general population/vulnerable subgrous during/after COVID-19. In adults, co-primary outcomes are change from pre-COVID-19 to intra-COVID-19 in well-being (WHO-5) and a composite psychopathology P-Factor. Key secondary outcomes are a P-extended factor, global mental and physical health. Secondary outcomes include health-service utilization/functioning, treatment adherence, functioning, symptoms/behaviors/emotions, substance ab-/use, violence.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>: Starting 04/26/2020, up to 01/27/2021 >120,000 people from 152 countries/six continents have participated. Representative samples of ≥1,000 adults have been collected in 15 countries. Overall, 48.7% had prior physical disorders, 18.0% had prior mental disorders, 17.0% were health care workers, 7.3% were aged ≥65 years, 11.5% were exposed to someone infected with COVID-19, 16.2% had been in quarantine, and 1.1% had been COVID 19-positive.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Limitations</h3><p>: Cross-sectional survey, preponderance of non-representative participants.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>: Results from COH-FIT will comprehensively quantify the impact of COVID-19, seeking to identify high-risk groups in need for acute and long-term intervention, and inform evidence-based health policies/strategies during this/future pandemics.</p>

psychiatry,clinical neurology
[The role of GABA-benzodiazepine receptor complex in affecting the anxiolytic effect of 3-hydroxypyridines--new non-benzodiazepine tranquilizers].

T. Voronina,L. D. Smirnov,U. Tilekeeva,K. M. Diumaev

Abstract:The experiments on rats, using conflict situation method, have established that anxiolytic effect of 3-hydroxypyridine derivative is removed by bicucullin and picrotoxin, but not by Ro 5-3663, specific antagonist of benzodiazepine receptors Ro 15-1788 and inversive antagonist ethyl beta-carboline-3-carboxylate. The data obtained suggest that GABA-chloriontophor complex is involved into the realization of 3-hydroxypyridine anxiolytic effect.
Protocol of a population-based prospective COVID-19 cohort study Munich, Germany (KoCo19)

Katja Radon,Elmar Saathoff,Michael Pritsch,Jessica Michelle Guggenbühl Noller,Inge Kroidl,Laura Olbrich,Verena Thiel,Max Diefenbach,Friedrich Riess,Felix Forster,Fabian Theis,Andreas Wieser,Michael Hoelscher,Abhishek Bakuli,Judith Eckstein,Günter Froeschl,Otto Geisenberger,Christof Geldmacher,Arlett Heiber,Larissa Hoffmann,Kristina Huber,Dafni Metaxa,Michel Pletschette,Camilla Rothe,Mirjam Schunk,Claudia Wallrauch,Thorbjörn Zimmer,Stephan Prückner,Christiane Fuchs,Jan Hasenauer,Noemi Castelletti,Eleftheria Zeggini,Michael Laxy,Reiner Leidl,Lars Schwettmann,

DOI: https://doi.org/10.1186/s12889-020-09164-9

IF: 4.5

2020-08-26

BMC Public Health

Abstract:Abstract Background Due to the SARS-CoV-2 pandemic, public health interventions have been introduced globally in order to prevent the spread of the virus and avoid the overload of health care systems, especially for the most severely affected patients. Scientific studies to date have focused primarily on describing the clinical course of patients, identifying treatment options and developing vaccines. In Germany, as in many other regions, current tests for SARS-CoV2 are not conducted on a representative basis and in a longitudinal design. Furthermore, knowledge about the immune status of the population is lacking. Nonetheless, these data are needed to understand the dynamics of the pandemic and hence to appropriately design and evaluate interventions. For this purpose, we recently started a prospective population-based cohort in Munich, Germany, with the aim to develop a better understanding of the state and dynamics of the pandemic. Methods In 100 out of 755 randomly selected constituencies, 3000 Munich households are identified via random route and offered enrollment into the study. All household members are asked to complete a baseline questionnaire and subjects ≥14 years of age are asked to provide a venous blood sample of ≤3 ml for the determination of SARS-CoV-2 IgG/IgA status. The residual plasma and the blood pellet are preserved for later genetic and molecular biological investigations. For twelve months, each household member is asked to keep a diary of daily symptoms, whereabouts and contacts via WebApp. If symptoms suggestive for COVID-19 are reported, family members, including children < 14 years, are offered a pharyngeal swab taken at the Division of Infectious Diseases and Tropical Medicine, LMU University Hospital Munich, for molecular testing for SARS-CoV-2. In case of severe symptoms, participants will be transferred to a Munich hospital. For one year, the study teams re-visits the households for blood sampling every six weeks. Discussion With the planned study we will establish a reliable epidemiological tool to improve the understanding of the spread of SARS-CoV-2 and to better assess the effectiveness of public health measures as well as their socio-economic effects. This will support policy makers in managing the epidemic based on scientific evidence.

public, environmental & occupational health
Persistent symptoms and clinical findings in adults with post-acute sequelae of COVID-19/post-COVID-19 syndrome in the second year after acute infection: population-based, nested case-control study

Raphael S Peter,Alexandra Nieters,Siri Göpel,Uta Merle,Jürgen M Steinacker,Peter Deibert,Birgit Friedmann-Bette,Andreas Niess,Barbara Müller,Claudia Schilling,Gunnar Erz,Roland Giesen,Veronika Götz,Karsten Keller,Philipp Maier,Lynn Matits,Sylvia Parthé,Martin Rehm,Jana Schellenberg,Ulrike Schempf,Mengyu Zhu,Hans-Georg Kräusslich,Dietrich Rothenbacher,Winfried V. Kern

DOI: https://doi.org/10.1101/2024.05.22.24307659

2024-05-22

Abstract:Objective: To assess risk factors for persistence vs improvement and to describe clinical characteristics and diagnostic evaluation of subjects with post-acute sequelae of COVID-19/post-COVID-19 syndrome (PCS) persisting for more than one year. Design: Nested population-based case-control study. Setting: Comprehensive outpatient assessment, including neurocognitive, cardiopulmonary exercise, and laboratory testing in four university health centres in southwestern Germany (2022). Participants: PCS cases aged 18 to 65 years with (n=982) and age and sex-matched controls without PCS (n=576) according to an earlier population-based questionnaire study (six to 12 months after acute infection, phase 1) consenting to provide follow-up information and to undergo clinical diagnostic assessment (phase 2, another 8.5 months [median] after phase 1). Main outcome measures: Relative frequencies of symptoms and health problems and distribution of symptom scores and diagnostic test results between persistent cases and controls. Additional analysis included predictors of changing case or control status over time with adjustments for potentially confounding variables. Results: At the time of clinical examination (phase 2), 67.6% of the initial cases (phase 1) remained cases, whereas 78.5% of the controls continued to report no health problems related to PCS. In adjusted analyses, predictors of improvement among cases were mild acute index infection, previous full-time employment, educational status, and no specialist consultation and not attending a rehabilitation programme. Among controls, predictors of new symptoms or worsening with PCS development were an intercurrent secondary SARS-CoV-2 infection and educational status. At phase 2, persistent cases were less frequently never smokers, had higher values for BMI and body fat, and had lower educational status than controls. Fatigue/exhaustion, neurocognitive disturbance, chest symptoms/breathlessness and anxiety/depression/sleep problems remained the predominant symptom clusters, and exercise intolerance with post-exertional malaise for >14 h (PEM) and symptoms compatible with ME/CFS (according to Canadian consensus criteria) were reported by 35.6% and 11.6% of persistent cases, respectively. In adjusted analyses, significant differences between persistent cases and stable controls (at phase 2) were observed for neurocognitive test performances, scores for perceived stress and subjective cognitive disturbances, symptoms indicating dysautonomia, depression and anxiety, sleep quality, fatigue, and quality of life. In persistent cases, handgrip strength, maximal oxygen consumption, and ventilator efficiency were significantly reduced. However, there were no differences in measures of systolic and diastolic cardiac function, in the level of pro-BNP blood levels or other laboratory measurements (including complement activity, serological markers of EBV reactivation, inflammatory and coagulation markers, cortisol, ACTH and DHEA-S serum levels). Screening for viral persistence (based on PCR in stool samples and SARS-CoV-2 spike antigen levels in plasma in a subgroup of the cases) was negative. Sensitivity analyses (pre-existing illness/comorbidity, obesity, PEM, medical care of the index acute infection) revealed similar findings and showed that persistent cases with PEM reported more pain symptoms and had worse results in almost all tests. Conclusions: This nested population-based case-control study demonstrates that the majority of PCS cases do not recover in the second year of their illness, with patterns of reported symptoms remaining essentially similar, nonspecific and dominated by fatigue, exercise intolerance and cognitive complaints. We found objective signs of cognitive deficits and reduced exercise capacity likely to be unrelated to primary cardiac or pulmonary dysfunction in some of the cases, but there was no major pathology in laboratory investigations. A history of PEM >14 h which was associated with more severe symptoms as well as with more objective signs of disease may be a pragmatic means to stratify cases for disease severity.
Predictors of non-recovery from fatigue and cognitive deficits after COVID-19: a prospective, longitudinal, population-based study

Tim J Hartung,Thomas Bahmer,Irina Chaplinskaya-Sobol,Jürgen Deckert,Matthias Endres,Katrin Franzpötter,Johanna Geritz,Karl G Haeusler,Grit Hein,Peter U Heuschmann,Sina M Hopff,Anna Horn,Thomas Keil,Michael Krawczak,Lilian Krist,Wolfgang Lieb,Corina Maetzler,Felipe A Montellano,Caroline Morbach,Christian Neumann,Carolin Nürnberger,Anne-Kathrin Russ,Lena Schmidbauer,Sein Schmidt,Stefan Schreiber,Flo Steigerwald,Stefan Störk,Thomas Zoller,Walter Maetzler,Carsten Finke,NAPKON Study Group

DOI: https://doi.org/10.1016/j.eclinm.2024.102456

IF: 15.1

2024-02-03

EClinicalMedicine

Abstract:Background: Despite the high prevalence and major disability associated with fatigue and cognitive deficits after SARS-CoV-2 infection, little is known about long-term trajectories of these sequelae. We aimed to assess long-term trajectories of these conditions and to identify risk factors for non-recovery. Methods: We analyzed longitudinal data from the population-based COVIDOM/NAPKON-POP cohort in Germany. Participants with confirmed SARS-CoV-2 infection were assessed at least 6 months (baseline) and again at least 18 months (follow-up) after infection using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Scale (cutoff ≤ 30) and the Montreal Cognitive Assessment (MoCA, cutoff ≤ 25). Predictors of recovery from fatigue or cognitive deficits between assessments were identified through univariate and multivariable logistic regression models. The COVIDOM study is registered at the German registry for clinical studies (DRKS00023742) and at ClinicalTrials.gov (NCT04679584). Findings: Between 15 November 2020 and 9 May 2023, a total of 3038 participants were assessed at baseline (median 9 months after infection) and 83% responded to invitations for follow-up (median 26 months after infection). At baseline, 21% (95% confidence interval (CI) [20%, 23%]) had fatigue and 23% (95% CI [22%, 25%]) had cognitive deficits according to cutoff scores on the FACIT-Fatigue or MoCA. Participants with clinically relevant fatigue (at baseline) showed significant improvement in fatigue scores at follow-up (Hedges' g [95% CI] = 0.73 [0.60, 0.87]) and 46% (95% CI [41%, 50%]) had recovered from fatigue. Participants with cognitive deficits showed a significant improvement in cognitive scores (g [95% CI] = 1.12 [0.90, 1.33]) and 57% (95% CI [50%, 64%]) had recovered from cognitive deficits. Patients with fatigue exhibiting a higher depressive symptom burden and/or headache at baseline were significantly less likely to recover. Significant risk factors for cognitive non-recovery were male sex, older age and <12 years of school education. Importantly, SARS-CoV-2 reinfection had no significant impact on recovery from fatigue or cognitive deficits. Interpretation: Fatigue and cognitive deficits are common sequelae after SARS-CoV-2 infection. These syndromes improved over time and about half of the patients recovered within two years. The identified risk factors for non-recovery from fatigue and cognitive deficits could play an important role in shaping targeted strategies for treatment and prevention. Funding: Funded by the German Federal Ministry of Education and Research (BMBF; grant number 01KX2121) and German Research Foundation (DFG) Excellence Cluster "Position Medicine in Information".
Mental health of individuals with pre-existing mental illnesses at the beginning of the COVID-19 pandemic: results of the German National Cohort (NAKO)

Janine Stein,Alexander Pabst,Klaus Berger,André Karch,Henning Teismann,Fabian Streit,Hans J Grabe,Rafael Mikolajczyk,Janka Massag,Wolfgang Lieb,Stefanie Castell,Jana-Kristin Heise,Matthias B Schulze,Sylvia Gastell,Volker Harth,Nadia Obi,Annette Peters,Marie-Theres Huemer,Patricia Bohmann,Michael Leitzmann,Sabine Schipf,Claudia Meinke-Franze,Antje Hebestreit,Daniela C Fuhr,Karin B Michels,Stefanie Jaskulski,Hannah Stocker,Lena Koch-Gallenkamp,Stefan N Willich,Thomas Keil,Markus Löffler,Kerstin Wirkner,Steffi G Riedel-Heller,for German National Cohort (NAKO) Consortium

DOI: https://doi.org/10.3389/fpubh.2024.1451631

2024-09-23

Abstract:Background: The COVID-19 pandemic prompted a range of studies on mental health, with mixed results. While numerous studies reported worsened conditions in individuals with pre-existing mental disorders, others showed resilience and stability in mental health. However, longitudinal data focusing on the German population are sparse, especially regarding effects of age and pre-existing mental disorders during the early stages of the pandemic. Objectives: To assess the interplay between psychiatric history, age, and the timing of the pandemic, with a focus on understanding how these factors relate to the severity of depression and anxiety symptoms. Methods: Exploratory analyses were based on 135,445 individuals aged 20-72 years from the German National Cohort (NAKO). Depressive and anxiety symptoms were assessed before and after the first wave of the pandemic. Inferential statistical analyses and negative binomial regression models were calculated. Results: Persons with a self-reported psychiatric history exhibited comparable levels of depression and anxiety symptom severity after the first wave of the pandemic compared to the time before. In contrast, individuals without a psychiatric history, particularly those in their 20s to 40s, experienced an increase in mental health symptom severity during the first wave of the pandemic. Limitations: Analyses focuses on the first wave of the pandemic, leaving the long-term mental health effects unexplored. Conclusion: Future research should consider age-specific and mental-health-related factors when addressing global health crises. Additionally, it is important to explore factors influencing resilience and adaptation, aiming to develop targeted interventions and informed policies for effective mental health management during pandemics.
Global and risk-group stratified well-being and mental health during the COVID-19 pandemic in adults: Results from the international COH-FIT Study

Marco Solmi,Trevor Thompson,Andrés Estradé,Agorastos Agorastos,Joaquim Radua,Samuele Cortese,Elena Dragioti,Davy Vancampfort,Lau Caspar Thygesen,Harald Aschauer,Monika Schlögelhofer,Elena Aschauer,Andres Schneeberger,Christian G Huber,Gregor Hasler,Philippe Conus,Kim Q Do Cuénod,Roland von Känel,Gonzalo Arrondo,Paolo Fusar-Poli,Philip Gorwood,Pierre-Michel Llorca,Marie-Odile Krebs,Elisabetta Scanferla,Taishiro Kishimoto,Golam Rabbani,Karolina Skonieczna-Żydecka,Paolo Brambilla,Angela Favaro,Akihiro Takamiya,Leonardo Zoccante,Marco Colizzi,Julie Bourgin,Karol Kamiński,Maryam Moghadasin,Soraya Seedat,Evan Matthews,John Wells,Emilia Vassilopoulou,Ary Gadelha,Kuan-Pin Su,Jun Soo Kwon,Minah Kim,Tae Young Lee,Oleg Papsuev,Denisa Manková,Andrea Boscutti,Cristiano Gerunda,Diego Saccon,Elena Righi,Francesco Monaco,Giovanni Croatto,Guido Cereda,Jacopo Demurtas,Natascia Brondino,Nicola Veronese,Paolo Enrico,Pierluigi Politi,Valentina Ciappolino,Andrea Pfennig,Andreas Bechdolf,Andreas Meyer-Lindenberg,Kai G Kahl,Katharina Domschke,Michael Bauer,Nikolaos Koutsouleris,Sibylle Winter,Stefan Borgwardt,Istvan Bitter,Judit Balazs,Pál Czobor,Zsolt Unoka,Dimitris Mavridis,Konstantinos Tsamakis,Vasilios P Bozikas,Chavit Tunvirachaisakul,Michael Maes,Teerayuth Rungnirundorn,Thitiporn Supasitthumrong,Ariful Haque,Andre R Brunoni,Carlos Gustavo Costardi,Felipe Barreto Schuch,Guilherme Polanczyk,Jhoanne Merlyn Luiz,Lais Fonseca,Luana V Aparicio,Samira S Valvassori,Merete Nordentoft,Per Vendsborg,Sofie Have Hoffmann,Jihed Sehli,Norman Sartorius,Sabina Heuss,Daniel Guinart,Jane Hamilton,John Kane,Jose Rubio,Michael Sand,Ai Koyanagi,Aleix Solanes,Alvaro Andreu-Bernabeu,Antonia San José Cáceres,Celso Arango,Covadonga M Díaz-Caneja,Diego Hidalgo-Mazzei,Eduard Vieta,Javier Gonzalez-Peñas,Lydia Fortea,Mara Parellada,Miquel A Fullana,Norma Verdolini,Eva Andrlíková,Karolina Janků,Mark J Millan,Mihaela Honciuc,Anna Moniuszko-Malinowska,Igor Łoniewski,Jerzy Samochowiec,Łukasz Kiszkiel,Maria Marlicz,Paweł Sowa,Wojciech Marlicz,Georgina Spies,Brendon Stubbs,Joseph Firth,Sarah Sullivan,Asli Enez Darcin,Hatice Aksu,Nesrin Dilbaz,Onur Noyan,Momoko Kitazawa,Shunya Kurokawa,Yuki Tazawa,Alejandro Anselmi,Cecilia Cracco,Ana Inés Machado,Natalia Estrade,Diego De Leo,Jackie Curtis,Michael Berk,Andre F Carvalho,Philip Ward,Scott Teasdale,Simon Rosenbaum,Wolfgang Marx,Adrian Vasile Horodnic,Liviu Oprea,Ovidiu Alexinschi,Petru Ifteni,Serban Turliuc,Tudor Ciuhodaru,Alexandra Bolos,Valentin Matei,Dorien H Nieman,Iris Sommer,Jim van Os,Therese van Amelsvoort,Ching-Fang Sun,Ta-Wei Guu,Can Jiao,Jieting Zhang,Jialin Fan,Liye Zou,Xin Yu,Xinli Chi,Philippe de Timary,Ruud van Winkel,Bernardo Ng,Edilberto Peña de León,Ramon Arellano,Raquel Roman,Thelma Sanchez,Larisa Movina,Pedro Morgado,Sofia Brissos,Oleg Aizberg,Anna Mosina,Damir Krinitski,James Mugisha,Dena Sadeghi-Bahmani,Farshad Sheybani,Masoud Sadeghi,Samira Hadi,Serge Brand,Antonia Errazuriz,Nicolas Crossley,Dragana Ignjatovic Ristic,Carlos López-Jaramillo,Dimitris Efthymiou,Praveenlal Kuttichira,Roy Abraham Kallivayalil,Afzal Javed,Muhammad Iqbal Afridi,Bawo James,Omonefe Joy Seb-Akahomen,Jess Fiedorowicz,Jeff Daskalakis,Lakshmi N Yatham,Lin Yang,Tarek Okasha,Aïcha Dahdouh,Jari Tiihonen,Jae Il Shin,Jinhee Lee,Ahmed Mhalla,Lotfi Gaha,Takoua Brahim,Kuanysh Altynbekov,Nikolay Negay,Saltanat Nurmagambetova,Yasser Abu Jamei,Mark Weiser,Christoph U Correll

DOI: https://doi.org/10.1016/j.psychres.2024.115972

2024-05-23

Abstract:International studies measuring wellbeing/multidimensional mental health before/ during the COVID-19 pandemic, including representative samples for >2 years, identifying risk groups and coping strategies are lacking. COH-FIT is an online, international, anonymous survey measuring changes in well-being (WHO-5) and a composite psychopathology P-score, and their associations with COVID-19 deaths/restrictions, 12 a-priori defined risk individual/cumulative factors, and coping strategies during COVID-19 pandemic (26/04/2020-26/06/2022) in 30 languages (representative, weighted non-representative, adults). T-test, χ2, penalized cubic splines, linear regression, correlation analyses were conducted. Analyzing 121,066/142,364 initiated surveys, WHO-5/P-score worsened intra-pandemic by 11.1±21.1/13.2±17.9 points (effect size d=0.50/0.60) (comparable results in representative/weighted non-probability samples). Persons with WHO-5 scores indicative of depression screening (<50, 13% to 32%) and major depression (<29, 3% to 12%) significantly increased. WHO-5 worsened from those with mental disorders, female sex, COVID-19-related loss, low-income country location, physical disorders, healthcare worker occupations, large city location, COVID-19 infection, unemployment, first-generation immigration, to age=18-29 with a cumulative effect. Similar findings emerged for P-score. Changes were significantly but minimally related to COVID-19 deaths, returning to near-pre-pandemic values after >2 years. The most subjectively effective coping strategies were exercise and walking, internet use, social contacts. Identified risk groups, coping strategies and outcome trajectories can inform global public health strategies.
Comparison of post-COVID-19 symptoms in patients infected with the SARS-CoV-2 variants delta and omicron—results of the Cross-Sectoral Platform of the German National Pandemic Cohort Network (NAPKON-SUEP)

Sina M. Hopff,Katharina S. Appel,Olga Miljukov,Johannes Schneider,Marylyn M. Addo,Robert Bals,Sven Bercker,Sabine Blaschke,Isabel Bröhl,Nikolaus Büchner,Hiwa Dashti,Johanna Erber,Anette Friedrichs,Ramsia Geisler,Siri Göpel,Marina Hagen,Frank Hanses,Björn-Erik Ole Jensen,Maria Keul,Adalbert Krawczyk,Bettina Lorenz-Depiereux,Patrick Meybohm,Milena Milovanovic,Lazar Mitrov,Carolin Nürnberger,Wilfried Obst,Christoph Römmele,Christian Schäfer,Christian Scheer,Margarete Scherer,Julia Schmidt,Kristina Seibel,Shimita Sikdar,Johannes Josef Tebbe,Phil-Robin Tepasse,Philipp Thelen,Maria J. G. T. Vehreschild,Christina Weismantel,J. Janne Vehreschild

DOI: https://doi.org/10.1007/s15010-024-02270-5

2024-05-08

Infection

Abstract:Purpose The influence of new SARS-CoV-2 variants on the post-COVID-19 condition (PCC) remains unanswered. Therefore, we examined the prevalence and predictors of PCC-related symptoms in patients infected with the SARS-CoV-2 variants delta or omicron. Methods We compared prevalences and risk factors of acute and PCC-related symptoms three months after primary infection (3MFU) between delta- and omicron-infected patients from the Cross-Sectoral Platform of the German National Pandemic Cohort Network. Health-related quality of life (HrQoL) was determined by the EQ-5D-5L index score and trend groups were calculated to describe changes of HrQoL between different time points. Results We considered 758 patients for our analysis (delta: n = 341; omicron: n = 417). Compared with omicron patients, delta patients had a similar prevalence of PCC at the 3MFU (p = 0.354), whereby fatigue occurred most frequently (n = 256, 34%). HrQoL was comparable between the groups with the lowest EQ-5D-5L index score (0.75, 95% CI 0.73–0.78) at disease onset. While most patients (69%, n = 348) never showed a declined HrQoL, it deteriorated substantially in 37 patients (7%) from the acute phase to the 3MFU of which 27 were infected with omicron. Conclusion With quality-controlled data from a multicenter cohort, we showed that PCC is an equally common challenge for patients infected with the SARS-CoV-2 variants delta and omicron at least for the German population. Developing the EQ-5D-5L index score trend groups showed that over two thirds of patients did not experience any restrictions in their HrQoL due to or after the SARS-CoV-2 infection at the 3MFU. Clinical Trail registration The cohort is registered at ClinicalTrials.gov since February 24, 2021 (Identifier: NCT04768998).

infectious diseases
Characterizing Long COVID in Children and Adolescents

Rachel S Gross,Tanayott Thaweethai,Lawrence C Kleinman,Jessica N Snowden,Erika B Rosenzweig,Joshua D Milner,Kelan G Tantisira,Kyung E Rhee,Terry L Jernigan,Patricia A Kinser,Amy L Salisbury,David Warburton,Sindhu Mohandas,John C Wood,Jane W Newburger,Dongngan T Truong,Valerie J Flaherman,Torri D Metz,Elizabeth W Karlson,Lori B Chibnik,Deepti B Pant,Aparna Krishnamoorthy,Richard Gallagher,Michelle F Lamendola-Essel,Denise C Hasson,Stuart D Katz,Shonna Yin,Benard P Dreyer,Megan Carmilani,K Coombs,Megan L Fitzgerald,Nick Güthe,Mady Hornig,Rebecca J Letts,Aimee K Peddie,Brittany D Taylor,Andrea S Foulkes,Melissa S Stockwell,RECOVER-Pediatrics Consortium,RECOVER-Pediatrics Group Authors,Venkataraman Balaraman,Amanda Bogie,Hulya Bukulmez,Allen J Dozor,Daniel Eckrich,Amy J Elliott,Danielle N Evans,Jonathan S Farkas,E Vincent S Faustino,Laura Fischer,Sunanda Gaur,Ashraf S Harahsheh,Uzma N Hasan,Daniel S Hsia,Gredia Huerta-Montañez,Kathy D Hummel,Matt P Kadish,David C Kaelber,Sankaran Krishnan,Jessica S Kosut,Jerry Larrabee,Peter Paul C Lim,Ian C Michelow,Carlos R Oliveira,Hengameh Raissy,Zaira Rosario-Pabon,Judith L Ross,Alice I Sato,Michelle D Stevenson,Maria M Talavera-Barber,Ronald J Teufel,Kathryn E Weakley,Emily Zimmerman,Marie-Abele C Bind,James Chan,Zoe Guan,Richard E Morse,Harrison T Reeder,Natascha Akshoomoff,Judy L Aschner,Rakesh Bhattacharjee,Lesley A Cottrell,Kelly Cowan,Viren A D'Sa,Alexander G Fiks,Maria L Gennaro,Katherine Irby,Manaswitha Khare,Jeremy Landeo Guttierrez,Russell J McCulloh,Shalu Narang,Manette Ness-Cochinwala,Sheila Nolan,Paul Palumbo,Julie Ryu,Juan C Salazar,Rangaraj Selvarangan,Cheryl R Stein,Alan Werzberger,William T Zempsky,Robin Aupperle,Fiona C Baker,Marie T Banich,Deanna M Barch,Arielle Baskin-Sommers,James M Bjork,Susan Y Bookheimer,Sandra A Brown,B J Casey,Linda Chang,Duncan B Clark,Anders M Dale,Mirella Dapretto,Thomas M Ernst,Damien A Fair,Sarah W Feldstein Ewing,John J Foxe,Edward G Freedman,Naomi P Friedman,Hugh Garavan,Dylan G Gee,Raul Gonzalez,Kevin M Gray,Mary M Heitzeg,Megan M Herting,Joanna Jacobus,Angela R Laird,Christine L Larson,Krista M Lisdahl,Monica Luciana,Beatriz Luna,Pamela A F Madden,Erin C McGlade,Eva M Müller-Oehring,Bonnie J Nagel,Michael C Neale,Martin P Paulus,Alexandra S Potter,Perry F Renshaw,Elizabeth R Sowell,Lindsay M Squeglia,Susan Tapert,Lucina Q Uddin,Sylia Wilson,Deborah A Yurgelun-Todd

DOI: https://doi.org/10.1001/jama.2024.12747

IF: 11.816

2024-08-21

JAMA

Abstract:Importance: Most research to understand postacute sequelae of SARS-CoV-2 infection (PASC), or long COVID, has focused on adults, with less known about this complex condition in children. Research is needed to characterize pediatric PASC to enable studies of underlying mechanisms that will guide future treatment. Objective: To identify the most common prolonged symptoms experienced by children (aged 6 to 17 years) after SARS-CoV-2 infection, how these symptoms differ by age (school-age [6-11 years] vs adolescents [12-17 years]), how they cluster into distinct phenotypes, and what symptoms in combination could be used as an empirically derived index to assist researchers to study the likely presence of PASC. Design, setting, and participants: Multicenter longitudinal observational cohort study with participants recruited from more than 60 US health care and community settings between March 2022 and December 2023, including school-age children and adolescents with and without SARS-CoV-2 infection history. Exposure: SARS-CoV-2 infection. Main outcomes and measures: PASC and 89 prolonged symptoms across 9 symptom domains. Results: A total of 898 school-age children (751 with previous SARS-CoV-2 infection [referred to as infected] and 147 without [referred to as uninfected]; mean age, 8.6 years; 49% female; 11% were Black or African American, 34% were Hispanic, Latino, or Spanish, and 60% were White) and 4469 adolescents (3109 infected and 1360 uninfected; mean age, 14.8 years; 48% female; 13% were Black or African American, 21% were Hispanic, Latino, or Spanish, and 73% were White) were included. Median time between first infection and symptom survey was 506 days for school-age children and 556 days for adolescents. In models adjusted for sex and race and ethnicity, 14 symptoms in both school-age children and adolescents were more common in those with SARS-CoV-2 infection history compared with those without infection history, with 4 additional symptoms in school-age children only and 3 in adolescents only. These symptoms affected almost every organ system. Combinations of symptoms most associated with infection history were identified to form a PASC research index for each age group; these indices correlated with poorer overall health and quality of life. The index emphasizes neurocognitive, pain, and gastrointestinal symptoms in school-age children but change or loss in smell or taste, pain, and fatigue/malaise-related symptoms in adolescents. Clustering analyses identified 4 PASC symptom phenotypes in school-age children and 3 in adolescents. Conclusions and relevance: This study developed research indices for characterizing PASC in children and adolescents. Symptom patterns were similar but distinguishable between the 2 groups, highlighting the importance of characterizing PASC separately for these age ranges.

[Minor salmonellosis in pediatrics: cases at the Pediatric Clinic I].

Definition of the Post-COVID syndrome using a symptom-based Post-COVID score in a prospective, multi-center, cross-sectoral cohort of the German National Pandemic Cohort Network (NAPKON)

Epidemiology of 7375 children and adolescents hospitalized with COVID-19 in Germany, reported via a prospective, nationwide surveillance study in 2020–2022

From first to second wave: follow-up of the prospective COVID-19 cohort (KoCo19) in Munich (Germany)

Analysis of acute COVID-19 including chronic morbidity: protocol for the deep phenotyping National Pandemic Cohort Network in Germany (NAPKON-HAP)

Intensive heart rhythm monitoring to decrease ischemic stroke and systemic embolism-the Find-AF 2 study-rationale and design

Long-term health sequelae and quality of life at least 6 months after infection with SARS-CoV-2: design and rationale of the COVIDOM-study as part of the NAPKON population-based cohort platform (POP)

Clinical Effectiveness of Newborn Screening for Spinal Muscular Atrophy

Phenotypes of disease severity in a cohort of hospitalized COVID-19 patients: Results from the IMPACC study

Characterising HIV-Indicator conditions among two nationwide long-term cohorts of people living with HIV in Germany (1999–2023)

Anonymity in Attribute-Based Group Signatures

Researching COVID to Enhance Recovery (RECOVER) adult study protocol: Rationale, objectives, and design

The collaborative outcomes study on health and functioning during infection times in adults (COH-FIT-Adults): Design and methods of an international online survey targeting physical and mental health effects of the COVID-19 pandemic

[The role of GABA-benzodiazepine receptor complex in affecting the anxiolytic effect of 3-hydroxypyridines--new non-benzodiazepine tranquilizers].

Protocol of a population-based prospective COVID-19 cohort study Munich, Germany (KoCo19)

Persistent symptoms and clinical findings in adults with post-acute sequelae of COVID-19/post-COVID-19 syndrome in the second year after acute infection: population-based, nested case-control study

Predictors of non-recovery from fatigue and cognitive deficits after COVID-19: a prospective, longitudinal, population-based study

Mental health of individuals with pre-existing mental illnesses at the beginning of the COVID-19 pandemic: results of the German National Cohort (NAKO)

Global and risk-group stratified well-being and mental health during the COVID-19 pandemic in adults: Results from the international COH-FIT Study

Comparison of post-COVID-19 symptoms in patients infected with the SARS-CoV-2 variants delta and omicron—results of the Cross-Sectoral Platform of the German National Pandemic Cohort Network (NAPKON-SUEP)

Characterizing Long COVID in Children and Adolescents